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“The basic mechanisms that regulate lung development and the link with human lung disease 
are among the most challenging and exciting areas of scientific inquiry”.  
 
Edward E. Morrisey  
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2 Abstract 
 
Bronchopulmonary dysplasia (BPD) is a chronic lung disease characterized by arrested 
alveolarization, a complication of premature birth. The gasotransmitter hydrogen sulfide (H2S) 
is emerging as a mediator of lung physiology and disease. In this study, the impact of systemic 
application of H2S on post-natal alveolarization was evaluated in a mouse BPD model. 
Exposure of newborn mice to 85% O2 for 10 days decreased the total number of alveoli in the 
lung by 56% and increased mean alveolar septal wall thickness by 29%, assessed by 
stereological analysis. Systemically administration of GYY4137, the slow-release H2S donor, 
for 10 days improved lung alveolarization in mouse pups breathing 85% O2, compared with 
vehicle-treated littermates. Though without effect on lung oxidative status, systemic H2S 
administration reduced leukocyte infiltration into alveolar airspaces caused by hyperoxia, and 
normalized lung interleukin (IL)-10 levels that were else diminished by 85% O2. The rapid-
release H2S donor NaHS was used to treat primary mouse alveolar type II (ATII) cells; NaHS 
had no impact on cell viability but stimulated ATII cell migration. Glibenclamide attenuated 
the impact of NaHS on ATII cell migration, implicating ion channels; and was accompanied by 
activation of Akt, hinting at two possible mechanisms of H2S action. Although exposure of 
ATII cells to 85% O2 produced substantial changes in gene expression, exposure to either 
GYY4137 or NaHS had no impact on ATII cell gene expression, as determined by microarray 
suggesting that the effects observed were independent of changes in gene expression. H2S can 
be generated endogenously by cystathionine -synthase (Cbs) and cystathionine -lyase (Cth). 
In this study it is demonstrated that the expression of Cbs and Cth in mouse lungs is dynamically 
regulated during lung alveolarization, and that alveolarization is impaired in Cbs-/- and Cth-/- 
mouse pups, where a 50% reduction in the total number of alveoli was observed, with no 
influence on mean alveolar septal wall thickness. Immunofluorescence staining and laser-
capture micro dissection revealed that CBS and CTH expression was present in the lung vessels 
and in the airway epithelium. Vessel remodeling occurred in the absence of Cbs and Cth, since 
it led to a 100-500% increase in vessel muscularization of small- and medium- size lung vessels. 
Inhibition of CBS or CTH expression in endothelial cells, using either small interfering RNA 
or via pharmacological inhibition (propargylglycine) respectively, diminished angiogenic 
capacity resulting in a 50% decrease in number of tubes formed, and a 30-40% decrease in tube 
length. On the other hand, administration of GYY4137, promoted endothelial tube formation. 
These data support the further investigation of H2S as a candidate interventional strategy to 
limit the impaired alveolarization associated with BPD, also suggests a key role for the 
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H2S-generating enzymes Cbs and Cth in lung alveolarization and pulmonary vascular 
development and homeostasis. 
 
3 Kurzfassung  
 
Die bronchopulmonale Dysplasie (BPD) ist eine chronische Lungenerkrankung, charakterisiert 
durch eine gehemmte Alveolarisierung und tritt als Komplikation bei Frühgeburten auf. Der 
Gasotransmitter Wasserstoffsulfid (H2S) ist als ein Mediator in der Lungenphysiologie und in 
Erkrankungen bekannt. In dieser Studie wurde die Wirkung einer systemischen Applikation 
von H2S auf die postnatale Alveolarisierung im BPD Modell evaluiert. Die Exposition 
neugeborener Mäuse zu 85% O2 für 10 Tage verringerte die totale Anzahl der Alveoli in der 
Lunge um 56% und erhöhte die durchschnittliche Wanddicke der alveolaren Septen um 29%, 
festgestellt durch stereologische Analysen. Die systemische Verabreichung von GYY4137, 
einem H2S Donor mit langsamer Freisetzung, für 10 Tage verbesserte die Alveolarisierung in 
den Jungtieren, die 85% O2 ausgesetzt waren, im Vergleich zu den Jungtieren, die nur die 
Trägersubstanz verabreicht bekamen. Ohne Effekte auf den oxidativen Status der Lunge 
reduzierte die systemische H2S Gabe die durch die Hyperoxie begründete Leukozyten-
Infiltration in den alveolären Luftraum und normalisierte die Interleukin (IL)-10 Level, die 
durch 85% O2 verringert werden. NaHS, ein H2S Donor mit schneller Freisetzung, wurde zur 
Behandlung primärer alveolärer Typ II (ATII) Zellen verwendet. NaHS hatte keine Auswirkung 
auf die Lebensfähigkeit der Zellen, stimulierte jedoch die Zellmigration. Glibenclamide 
verringerte die Wirkung von NaHS auf die ATII Zellmigration, was eine Rolle von 
Ionenkanälen in diesem Prozess impliziert und wurde durch die Aktivierung von Akt begleitet, 
was Hinweise auf zwei mögliche Mechanismen der H2S Aktivität gibt. Obwohl die Exposition 
von ATII Zellen zu 85% O2 erhebliche Veränderungen der Genexpression bewirkt, hatte weder 
die Exposition zu GYY4137 noch zu NaHS eine Wirkung auf die Genexpression der ATII 
Zellen, wie durch Microarray Analysen festgestellt wurde. Dies lässt vermuten, dass die 
beobachteten Effekte unabhängig von Veränderungen in der Genexpression sind. H2S kann 
endogen durch die Cystathionin β-Synthase (Cbs) und die Cystathionin -Lyase (Cth) generiert 
werden. In dieser Studie wurde gezeigt, dass die Expression von Cbs und Cth in der Lunge der 
Maus während der Alveolarisierung dynamisch reguliert wird und dass die Alveolarisierung in 
Cbs-/- und Cth-/- Jungtieren der Maus beeinträchtigt ist. Hier wurde eine Reduzierung der totalen 
Anzahl von Alveolen um 50% beobachtet, ein Einfluss auf die durchschnittliche Wanddicke 
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der alveolaren Septen wurde nicht festgestellt. Immunofluoreszenzfärbungen und 
Lasermikrodissektionen zeigten, dass eine Expression von CBS und CTH in den 
Lungengefäßen und dem Epithelium der Atemwege stattfand. Bei Abwesenheit von Cbs und 
Cth wurde ein Blutgefäß-Remodeling festgestellt, was zu einer 100 – 500%-igen Zunahme der 
Muskularisierung der kleinen und mittleren Blutgefäße führte. Die Inhibierung der CBS oder 
CTH Expression in Endothelzellen, entweder unter Verwendung von small interfering RNA 
oder einer pharmakologisch wirksamen Substanz (Propargylglycin) verminderte die angiogene 
Kapazität mit dem Resultat einer um 50% verminderten Anzahl der formierten tubes und einer 
Reduzierung der Länge der formierten tubes um 30 – 40%. Die Verabreichung von GYY4137 
förderte die endotheliale tube Formierung. Diese Daten unterstützen eine weitere Untersuchung 
des H2S als einen Kandidaten für Interventionsstrategien, um der beeinträchtigten 
Alveolarisierung, die mit BPD assoziiert ist, zu begegnen. Weiterhin kann vermutet werden, 
dass die H2S-generierenden Enzyme Cbs und Cth in der Alveolarisierung und der pulmonalen 
vaskulären Entwicklung und Homöostase eine Schlüsselrolle einnehmen.  
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8 Introduction 
 
 Lung development 
 
The pulmonary system develops from a series of complex events that occur during prenatal and 
early postnatal life. During lung development, the embryonic lung arises as a protrusion from 
the foregut endoderm and undergoes a process called “branching morphogenesis”, which begins 
a reproducible, bilaterally asymmetrical pattern of stereotypic branching into the surrounding 
splanchnic mesenchyme.  
In the human lung, the branching is completed after 16 generations by week 16 post conception, 
and three lobes form on the right side and two on the left side of the lungs. These events require 
correct growth and differentiation of the epithelial and mesenchymal components of the 
immature lung to form the bronchial tree and alveoli; the pulmonary, bronchial, and lymphatic 
vasculatures; the nerves and the pleura.  
In contrast to humans, the mouse has four lobes in the right side and one lobe on the left side. 
Moreover, the mouse only has 12 airway generations and alveolarization occurs postnatally.  
Classically, lung development has been classified into five stages: embryonic, pseudoglandular, 
canalicular, terminal saccular, and alveolar. Lung development is an early process that starts 
around the third week of the embryonic period and that can last until early adulthood. During 
the earliest lung development stage, the pseudoglandular stage (5-17 weeks of human 
pregnancy, embryonic (E) E9.5-E16.6 days in the mouse embryo), branching morphogenesis 
occurs in epithelial tubes lined with cuboidal epithelial cells. At this point, the structure is still 
too immature for adequate gas exchange. During the canalicular stage (16-25 weeks of human 
pregnancy, E16.6-E17.4 days in the mouse embryo), the respiratory tree continues growing in 
length and diameter, along with vascularization and angiogenesis. An increase in capillary 
number occurs, and the terminal bronchioles are divided into respiratory bronchioles and 
alveolar ducts. The terminal saccular stage (24 weeks to late fetal period in human, E17.4 to 
postnatal (P) day P5 in the mouse) is characterized by thinning of the interstitium. The alveolar 
epithelial cells are more clearly differentiated into type I and type II pneumocytes. The 
capillaries grow and form an intricate network during this stage and the lymphatic network 
becomes well developed. Maturation of surfactant synthesis and secretion is a crucial event to 
prevent lungs from collapsing and allow gas exchange, and near the end of this stage, the fetal 
lung can support gas exchange in premature newborns. During the alveolar stage (late fetal 
period to childhood in human, P5 to P30 in mouse) terminal sacs develop into mature alveolar 
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ducts and alveoli. Contrary to early lung development, this stage remains poorly understood. 
During this latter phase of development, important events take place for the maturation of the 
lung: the peak of secondary septation occurs, with an increase in the number and a decrease in 
the size of the alveoli, together with a thinning of the pulmonary septa and maturation of the 
lung microvasculature, increasing exponentially the surface area for gas exchange and 
minimizing the distance between air and blood. A neonatal lung is estimated to have about 50 
million alveoli, still, this number increases six-fold to about 300 million by the age 7-8 years 
when alveolarization is largely complete. In the meantime, the adult alveolar capillary bed is 
able of accommodating the entire cardiac output of 5 L/min, rising five-fold to 25 L/min during 
maximal exercise (Madurga et al., 2013; Massaro & Massaro, 2007; Morrisey et al., 2013; 
Warburton, 2012; Warburton et al., 2010; Warburton et al., 2000). 
 
 
 
 
Figure 1 Scheme of the stages of lung development.   
Scheme of the five stages of lung development: embryonic, pseudoglandular, canalicular, terminal 
saccular, and alveolar. In mice, birth takes place after 20 days of embryonic development and pups are 
born in the saccular stage. In contrast, humans give birth around the 38th week of gestation, during the 
alveolar stage of lung maturation. GD, gestational day, P, postnatal day. With the permission of Dr. 
Gianni Carraro. 
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 Bronchopulmonary dysplasia 
 
8.2.1 Introduction  
 
The development of the airways, through epithelial tube branching and later septation of 
terminal air sacs, occurs in close conjunction with the development of the pulmonary 
vasculature. Alterations to these developmental processes give rise to abnormal lung structure, 
deficiency of gas exchange, and newborn respiratory failure. Clinical examples of such 
perturbation of normal lung growth include bronchopulmonary dysplasia (BPD), cystic 
adenomatoid malformation of the lung, and hypoplasia of the lung (Smith et al., 2010; 
Warburton et al., 2010). 
 
8.2.2 Definition  
 
The term bronchopulmonary dysplasia was first described in 1967 by Northway and colleagues 
(Northway et al., 1967). The definition of BPD is complicated and has evolved over the years. 
Nowadays, BPD refers to a newborn at 35-37 weeks postmenstrual age treated with mechanical 
ventilation, continuous positive airway pressure (CPAP), or in need of oxygen concentrations 
of 30% at rest on oxygen saturation (sO2) of 90-96% or supplemental oxygen concentrations of 
30% on sO2 of more than 96% (Ambalavanan & Carlo, 2004; Ehrenkranz et al., 2005; Jobe & 
Bancalari, 2001; Jobe, 1999; Northway, 1992; Walsh et al., 2004). 
The National Institute for Health in the USA has further divided the definition of BPD into: 
-Mild: Requiring supplemental O2 at 28 weeks of age, but in air by 36 weeks corrected age. 
-Moderate: Requiring <30% supplemented O2 at 36 weeks corrected age. 
-Severe: Requiring >30% supplemental O2 and/or requiring CPAP or ventilation, at 36 weeks 
of corrected age. 
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8.2.3 Incidence and prevalence 
 
The BPD disease is a complex multifactorial chronic lung disease of the premature newborn 
that affects thousands of infants each year with an incidence of 23% of infants with birth 
weights are below 1500 g. It is the single most important factor determining the length of 
hospital stay in newborns born at less than 29 weeks. The more premature the newborns are, 
the more severely affected they are. The prevalence is higher among very low birth weight and 
extremely preterm infants. Improved medical management of BPD has increased substantially 
the survival of these patients and also the pathophysiological picture of BPD, but the prevalence 
of BPD has also increased, especially in small infants who may have been exposed to in utero 
infection (Bose et al., 2011; Laughon et al., 2011; Shennan et al., 1988; Van Marter, 2009).  
 
8.2.4 Morbidity and mortality 
 
Improvement in clinical management has decreased substantially the mortality rates of BPD 
infants. The survival and morbidity among infants older than 24 weeks of gestational age have 
improved since the introduction of antenatal corticosteroids treatment and surfactant therapy, 
and nowadays infants with BPD usually have a milder disease. However, the survival rate 
remain 25-50% in the most preterm neonates of 23-24 weeks gestation, reflecting the lack of 
maturation in alveolarization and vascular development. Neonates with severe BPD remain at 
high risk for mortality and pulmonary morbidity during the first two years of life. Finally, 
factors such as gender affect the severity of this disease, since male infants usually have a more 
severe phenotype with worse neurodevelopmental outcome (Ambalavanan et al., 2009; 
Ambalavanan et al., 2008; Ambalavanan et al., 2011; Shennan et al., 1988). 
 
8.2.5 Risk factors 
 
The BPD disease may be caused by factors such as perinatal infection (chorioamnionitis), 
peripartum inflammation, volotrauma, borotrauma, postnatal steroid treatment, premature 
delivery, and prolonged mechanical ventilation, among others (Ambalavanan et al., 2009; Bose 
et al., 2011; Hartling et al., 2012; Jobe, 2005; Jobe & Ikegami, 2001; Kakkera et al., 2005; 
Kallapur & Jobe, 2006; Kunzmann, et al., 2013; Laughon et al., 2011; Rocha et al., 2010; 
Schelonka et al., 2005). 
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8.2.6 Signs and symptoms 
 
Infants with BPD exhibit abnormalities during clinical examination, chest radiography, 
pulmonary function testing, and histopathologic studies. Initial abnormalities are consistent 
with respiratory distress syndrome which if they persist have a higher risk of evolving into 
BPD. The symptoms include the following: Tachypnea, tachycardia, increased respiratory 
effort (with nasal flaring, retractions and grunting), frequent desaturations and significant 
weight loss during the first ten days of life.  
Infants with BPD are usually extremely immature and have a very low weight birth. Often the 
requirements of oxygen and ventilator support are higher during the first two weeks of life. At 
weeks 2-4, either oxygen supplementation, ventilator support, or both, are frequently increased 
to maintain adequate ventilation and oxygenation. A classic scenario is a 23-26 weeks gestation 
infant who over a period of 4-10 weeks progresses from mechanical ventilation, CPAP through 
to requiring additional oxygen (Bancalari et al., 1979; Stoelhorst et al., 2005). 
 
8.2.7 Pathophysiology   
 
The pathogenesis of BPD remains poorly understood. Premature birth and subsequent events 
likely interfere with alveolarization and vascularization, leading to a decrease in alveolar 
number, and overall to a reduced surface area for gas exchange. Today, BPD is characterized 
by arrested alveolarization in the saccular stage, lung inflammation with variable interstitial 
fibrosis and discontinuance of microvessel maturation (Abman, 2007; Blackwell et al., 2011; 
Madurga et al., 2013; Morrisey et al., 2013; O'Reilly et al., 2013). 
 
8.2.8 Diagnosis 
 
Today, the diagnosis of BPD is defined by oxygen need and postmenstrual age, but the 
pathological characteristics and mechanisms that underlie the disease remain to be better 
understood. Different tests and procedures are useful tools for the diagnosis and monitoring, 
BPD such as laboratory tests (blood gasometry tests), oxygenation monitoring, chest 
radiography, high-resolution chest computed tomography scanning, chest magnetic resonance 
imaging, lung biopsy, pulmonary function tests (airway resistance, lung compliance, and airway 
reactivity) and echocardiographic assessment (Ambalavanan & Carlo, 2004; Bancalari et al., 
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1979; Jobe & Bancalari, 2001; Smith et al., 2005; Stoelhorst et al., 2005; Van Marter et al., 
2000; Walsh et al., 2006; Walsh et al., 2004). 
 
  
 
Figure 2 Chest X-ray of a one month old female patient with BPD.  
Initial chest X-ray revealing minimal coarsening of the interstitial markings radiating from the hilia. One 
month later after prolonged incubation, the chest X-ray reveals bilateral, interstitial thickening and 
diffuse haziness in the lungs. Courtesy of Northeastern Ohio Universities College of Medicine-Canton 
Affiliated Hospitals. 
 
8.2.9 Treatment 
 
In most therapies, BPD infants are treated by surfactant replacement (Kresch & Clive, 1998; 
Mbuyamba et al., 1998), with oxygen supplementation, CPAP and mechanical ventilation 
(Northway et al., 1967). Different models and strategies of ventilation have been studied to 
potentially reduce lung injury and systematic reviews judge that optimal use of conventional 
ventilation may be as effective as high-frequency oscillatory ventilation in improving 
pulmonary outcomes. Many centers use “gentler ventilation” with more CPAP and less 
intubation to lower the rates of BPD. Infants with BPD that require mechanical ventilation, 
small tidal volumes are preferable to lower the risk of lung injury, although in the very preterm 
infants, higher tidal volumes are necessary to maintain effective ventilation (Morley et al., 2008; 
Nanan et al., 2008). For infants requiring oxygen and positive pressure ventilation (PPV), 
efforts are made to minimize oxygen toxicity, lung, and retina injury. Optimal ventilation levels 
include a pH level of 7.2-7.3, a partial pressure of carbon dioxide of  45-55 mm Hg, and a partial 
pressure of oxygen level of 50-70 mm Hg (with sO2 at 91-95 %) (Network et al., 2010). 
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Nonetheless, the normal oxygen requirement for a preterm infant is unknown, and repeated 
episodes of desaturation and hypoxia may appear in infants with BPD receiving mechanical 
ventilation, as a result of altered pulmonary mechanics, bronchospasm, excessive stimulation, 
decreased of respiratory drive and enforced exhalation efforts. 
The use of other medications is also common, diuretics, bronchodilators and corticosteroids, 
which have many pharmacologically benefits but clinically significant adverse effects (Brion 
& Soll, 2001; Brundage et al., 1990; Halliday & Ehrenkranz, 2001a, 2001b, 2001c; Kersbergen 
et al., 2013; Papile et al., 1998). Patients with BPD have higher nutrition requirements, therefore 
nutritional strategies are important to manage these infants: Early administration of parenteral 
nutrition, supplementation with antioxidant vitamins (vitamin A), and caffeine treatment, avoid 
of fluid overload and early enteral feeding in small amounts (Darlow & Graham, 2007; Rocha 
et al., 2010; Schmidt et al., 2006). Postnatal growth failure is frequent in BPD patients, and may 
have extensive effects on long-term development outcomes. Therefore, strategies to optimize 
postnatal weight gain are necessary to improve pulmonary, retinal and neurologic development. 
Prenatal management of the pregnant mother to lower the risk of BPD includes treatment of 
maternal inflammatory conditions (chorioamnionitis) and treatment of maternal infection 
(Ureaplasma urealyticum) (Hartling et al., 2012; Schelonka et al., 2005). 
Overall, present therapies palliate the symptoms, but there is a lack of better treatments that 
promote lung maturation, and prognostic factors to detect which neonates are more prone to 
develop BPD (Jobe, 2011; Madurga et al., 2013).  
 
8.2.10 Complications 
 
Patients with BPD have a higher risk of developing pulmonary hypertension and cor pulmonale, 
which affects at least one in six extremely low birth weight infants with moderate-severe BPD, 
which increases the morbidity and mortality rates. Infants with BPD are at high risk of 
respiratory infections in the first two years of life (respiratory syncytial virus) that can endanger 
the life of these babies. Infants with BPD are at higher risk of poor growth and abnormal neuro- 
and lung- development. Chronic pulmonary morbidities are common in BPD infants. Abnormal 
growth occurs in 50-60% of infants with BPD. Patients with BPD have more than double risk 
to suffer neurodevelopmental impairment, cerebral palsy and low intelligent quotient. Other 
risks include severe retinopathy of prematurity, hearing impairment, severe intraventricular 
hemorrhage and ventriculomegaly (Ambalavanan et al., 2008; Ambalavanan et al., 2011; Bader 
et al., 1987; Kirpalani et al., 2006; Massie et al., 2011; O’Reilly et al., 2013). 
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8.2.11 Prognosis  
 
Most neonates with BPD survive but are at high risk for long-term pulmonary and neurologic 
sequelae. Persistent pulmonary hypertension or right ventricular hypertrophy are associated 
with a poor prognosis (Ambalavanan et al., 2008; Bader et al., 1987; Blayney et al. 1991; 
Kirpalani et al., 2006; Laughon et al., 2011; Massie et al., 2011; O'Reilly et al., 2013; Shennan 
et al., 1988; Smith et al., 2005). 
 
 Hydrogen sulfide 
 
8.3.1 Introduction to gasotransmitters 
 
The gasotransmitter family consists of three endogenous molecules of gases or gaseous 
signaling molecules: nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide (H2S). 
The criteria defining gasotransmitters were proposed by Rui Wang in 2003 (Wang, 2003): (i) 
Gasotransmitters are small molecules of gas (ii) that are freely permeable to membranes, and 
can have endocrine, paracrine and autocrine effects. (iii) Gasotransmitters are endogenously 
and enzymatically generated, and their production is regulated. Moreover, (iv) gasotransmitters 
have specific functions at specific physiologically relevant concentrations, and (v) their 
functions can be mimicked by exogenously applied counterparts. Finally, (vi) the cellular effect 
of gasotransmitters may or may not be mediated by second messengers but should have specific 
and molecular targets. The gasotransmitters NO, CO, and H2S are different from classic 
neurotransmitter and humoral factors while sharing some common characteristics, as it is 
documented in Table 1, first described in 1981 from clinical work with NO as a molecule that 
transmits information between cells in various parts of the body (Gillman & Lichtigfeld, 1981, 
1983). 
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Table 1 Comparison of the modes of action of gasotransmitters and neurotransmitters. 
 
 Release Re-uptake Removal mechanism Revert direction Membrane 
receptors 
Gasotransmitter Cytoplasm 
release 
No Nonenzymatic: 
oxidation, 
scavenging, 
methilation, etc. 
Bidirectional Not 
necessary 
Neurotransmitter Exocytotic 
vesicle 
Yes Enzyme dependent Pre-  
postsinaptic 
membrane (one 
direction) 
Necessary 
 
Under physiological conditions gasotransmitters are maintained at low levels, ensuring 
homeostasis of specific cells and organs, since the effects may not always be beneficial 
(gasotransmitters may cause inhibition of physiological cellular function). Nevertheless, these 
three gasotransmitters function in a regulatory capacity, controlling important physiologic 
functions including host defense against pathogens, vascular tone, apoptosis, neuromodulation, 
and energy metabolism (Kajimura et al., 2010). 
  
8.3.2 Nitric oxide and carbon monoxide 
 
The molecule NO was established as gasotransmitter in the brain and peripheral nervous system 
as a physiologic vasodilator, and NO is responsible of tumoricidal and bactericidal actions of 
macrophages. The physiologic role of NO as an endothelial derived relaxing factor is very well-
known. The generation of NO is through the enzyme NO synthase (NOS), which has three 
different isoforms derived from different genes that convert arginine to citrulline and NO 
(Gadalla & Snyder, 2010). The neuronal NOS (nNOS) is localized in the brain and peripheral 
nervous system and in few non-neural tissues, whereas endothelial NOS (eNOS) generates NO 
that regulates blood vessels and inducible NOS (iNOS) is present ubiquitously throughout the 
body, but with highest abundance in inflammatory cells (macrophages). The nNOS and eNOS 
are calcium-calmodulin dependent constitutive enzymes, meanwhile iNOS is an inducible 
enzyme, produced in response to inflammatory stimuli, and is not dependent on calcium. The 
NO binds with high affinity to the heme group in the active site of soluble guanylyl cyclase 
(sGC), promoting the catalytic activity of the enzyme. Generation of cGMP leads to smooth 
muscle cell relaxation. The concentration of NO in tissues is likely to be in the 0.1 to 100 nM 
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range, but it has been noted of having a higher concentration up to 500 to 600 nM in arterioles 
(Kajimura et al., 2010). 
The CO gasotransmitter is physiologically generated and can mediate neural activity in the 
brain and non-adrenergic non-cholinergic neurotransmission in the intestine. The CO molecule 
is enzymatically generated through two different isoforms of the enzyme heme oxygenase, 
heme oxygenase 1 (HMOX 1) and 2 (HMOX 2), with HMOX 1 being inducible, particularly 
activated through stressful and oxidative situations, and highly expressed in different tissues 
such as liver, kidney and spleen in the micromolar range. The HMOX 1 enzyme is responsible 
of degrading heme into biliverdin and CO (Kajimura et al., 2010; Nicholson & Calvert, 2010). 
In contrast, HMOX 2 is constitutively expressed and activated by calcium-calmodulin, much 
like nNOS and eNOS, and is mainly localized in the brain and the endothelial layer of blood 
vessels. The CO molecule also activates sGC but it is less potent than NO. Like eNOS and 
HMOX 2, CO is localized in the endothelial layer of blood vessels and behaves as an endothelial 
relaxing factor (Gadalla & Snyder, 2010). 
 
8.3.3 Introduction to hydrogen sulfide  
 
Hydrogen sulfide is an endogenous gas, considered to be the third gasotransmitter together with 
NO and CO, first described in 1989 as an endogenous “sulphide” in rat brain tissues and in 
normal human post-mortem brainstem that suggested endogenous production of H2S in the 
brain (Nicholson & Calvert, 2010; Wang, 2010). In 1996 Abe and Kimura reported the role of 
H2S in human neuromodulation that was the beginning of research into H2S as a biological 
signaling molecule (Gu & Zhu, 2011). Nowadays, it is acknowledged that H2S is produced 
endogenously in mammals in the brain, blood vessels, liver, kidneys, lung, upper and lower 
gastrointestinal tract, reproductive organs, synovial joints, connective tissue, cochlea and 
adipose tissues. The H2S molecule is implicated in a series of physiological and pathological 
processes in humans (Kabil et al., 2011; Predmore et al., 2012). 
 
8.3.4 Biochemistry of hydrogen sulfide under physiological conditions 
 
The H2S is small, lipid and water-soluble molecule and acts as a weak acid. The H2S molecule 
can interact with receptors and can pass through biological membranes to employ its effects. 
At 37 ºC and pH 7.4 in aqueous solution, two thirds of H2S dissociates into protons and HS
- 
and one third of H2S does not dissociate. The H2S molecule is presumed to exist in an ionized 
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form in extracellular fluids and plasma as HS- whereas within the cell (pH about 7.2) the 
amounts of H2S and HS
- are nearly equal (Nicholson & Calvert, 2010; Predmore et al., 2012).  
 
8.3.5 Hydrogen sulfide donors 
 
There are reagents that are able to release H2S, which have been very useful tools to study the 
biological effects and drug development of H2S. The most frequently used H2S donor in 
biological experiments is NaHS. Considered a fast release donor, NaHS can release H2S within 
seconds in aqueous solutions (Li et al., 2008). On the other hand, GYY4137 is a slow-release 
H2S donor that mimics in a more physiological way the actions of H2S; the GYY4137 
compound was synthesized by the Moore group on the basis of the structure of Lawesson’s 
compound, which releases H2S in organic solvents. The rate of H2S release from GYY4137       
(1 mmol/L) is 4.17±0.5 nmol/25min in aqueous solution, and when incubated in aqueous buffer 
(pH 7.4, 37 ºC), the rate of H2S release climbs for 15 min and then plateaus at 75 min. Release 
of H2S from GYY4137 is pH and temperature dependent, with less release at 4 ºC and more 
release at pH 3.0 (Li et al., 2008). When administered intravenously or intraperitonealy, 
GYY4137 increases plasma H2S at 30 min and H2S plasma levels remain elevated over 180 
min time course. In contrast, NaHS does not elevate plasma H2S at these time points (Li et al., 
2008). It has been proved that GYY4137 has vasorelaxant effects, antihypertensive and anti-
inflammatory activity, showing that GYY4137 is a useful tool for studying the biological effects 
of H2S (Gu & Zhu, 2011; Lee et al., 2011; Li et al., 2008). 
 
8.3.6 Toxicology of hydrogen sulfide 
 
The presence of H2S in the environment is easily recognized by the peculiar smell of rotten 
eggs. The H2S gas has been regarded as a toxic pollutant for decades, since small concentrations 
of this gas can make the perceived quality of the air as unpleasant (1-3 ppm). With increasing 
concentrations, in an extremely dose-effect response and duration of exposure, H2S can cause 
symptoms such as irritation of the eyes and the respiratory tract (20-50 ppm), headache, loss of 
appetite and decline in cognitive functions (200-500 ppm). When the concentration reaches 
around 1000 ppm H2S can be lethal due to saturation of the mitochondria and inhibition of 
cytochrome c oxidase (Gu & Zhu, 2011; Kabil et al., 2011; Mathew et al., 2011; Olson, 2011). 
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8.3.7 Endogenous hydrogen sulfide synthesis, regulation and catabolism 
 
Cysteine is a semi-essential amino acid and one of the two sulfur-containing amino acids 
together with methionine. The source of cysteine is the diet, and partly also methionine 
processing. Cysteine is the major source of H2S in mammals and H2S is generated mainly 
through three different enzymes (Figure 3): cystathionine β-synthase (Cbs), cystathionine γ-
lyase (Cth, also called Cse and Cgl) and 3-mercaptopyruvate sulfur transferase (Mpst) 
(Nicholson & Calvert, 2010; Olson, 2011; Wang, 2010). In most peripheral tissues Cth levels 
are much higher than the levels of Cbs, while in the brain Cbs is the most predominant form 
(Nagahara, 2011; Robert et al., 2003). In lower amounts, Mpst has been found in the brain, 
mostly in neurons, and in the vascular endothelium (Gu & Zhu, 2011; Olson, 2011; Wang, 
2010). Both Cbs and Cth are localized in the cytosol whereas Mpst exist both in the 
mitochondria and in the cytosol (Kajimura et al., 2010; Predmore et al., 2012). The Cbs enzyme 
condenses homocysteine with serine to generate the thiol ether cystathionine, during the 
condensation the hydroxyl group of serine is replaced with the thiolate of homocysteine. The 
human Cbs gene is located in chromosome 21 at 21q22.3. In humans and rats Cbs exists 
primarily as a homotetramer with a subunit molecular mass of 63 kDa. Each subunit also binds 
to the cofactors pyridoxal 5-phosphate (PLP), S-adenosyl methionine (SAM) and heme. The 
cofactor SAM is an allosteric activator of the Cbs enzyme while heme appears to be a redox 
sensor. The C-terminus of Cbs contains two domains of tandem repeats that seem to inhibit the 
enzymatic function, as the deletion of these domains activates Cbs. The Cbs enzyme can be 
sumoylated, inhibiting the catalytic activity of Cbs. The Cth enzyme can also form H2S from 
cysteine, it hydrolyzes cystathionine into cysteine with ammonia and α-ketobutyrate as 
byproducts. The Cth enzyme converts cysteine to thiocysteine, pyruvate and ammonia, in a β-
disulfide elimination reaction, with the thiocysteine then reacting with cysteine or other thiols 
to produce H2S and cysteine or the corresponding disulfide. The Cth enzyme is also dependent 
on PLP, and it is selectively activated by calcium-calmodulin similar to the activation of eNOS, 
nNOS and HMOX 2 (Gadalla & Snyder, 2010). The Mpst enzyme catalyzes only sulfur 
transferases reactions from 3-mercaptopyruvate to various donors, and needs cysteine 
aminotransferase and further redox reactions with biological thiols such as glutathione to yield 
H2S (Gu & Zhu, 2011; Predmore et al., 2012; Wang, 2010). 
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Figure 3 Potential pathways of H2S production and metabolism.  
Transsulfuration reactions that involve cystathionine β-synthase (Cbs), cystathionine γ-lyase (Cth) and 
3-mercaptopyruvate sulfur transferase (Mpst) in the production and metabolism of H2S. CDO, cysteine 
dioxygenase; CAT, cysteine aminotransferase; CLY, cysteine lyase; CSD, cysteine sulfinate 
decarboxylase CA, carbonic anhydrase; R-SH, thiol; GSSG, glutathione oxidized form. (Olson, 2011). 
 
The catabolic pathways of H2S are not fully understood, one catabolic pathway of H2S is 
oxidation in the mitochondria and excretion in the urine, sulfate being the major end product of 
H2S catabolism. Another catabolism pathway is the thiol S-methyltransferase mediated 
methylation of H2S to yield monomethylsulfide and dimethylsulfide. A third pathway involves 
binding of H2S to methemoglobin to yield sulfhemoglobin. It has also been reported that H2S 
can diffuse across the alveolar membrane (Kajimura et al., 2010). 
 
8.3.8 Cbs-/- and Cth-/- mice  
 
The Cbs-/- mice were generated through insertion of a neomycin selection cassette that replaced 
a genomic fragment containing exons 3 and 4 of the Cbs gene (Watanabe et al., 1995). The  
Cbs-/- mice have a manifest phenotype and are broadly used as a mental retardation model, as a 
model for hyperhomocysteinemia and as a thromboembolism model. The Cbs-/- mice display 
several pathophysiologic features similar to hyperhomocysteinemic patients, including 
endothelial dysfunction and hepatic steatosis. The mice usually die during the weaning period 
between the 2-4 weeks of age, probably due to severe hepatic dysfunction and require sufficient 
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supplementation of cysteine for survival. The Cbs-/- mice have a severe retardation in body mass 
that might be caused by taurine deficiency and an abnormal lipid metabolism. The Cbs-/- mice 
also have cerebellar malformation and impaired learning ability. The adult Cbs-/- mice display 
lung fibrosis and airspace enlargement in the absence of increased inflammatory cell infiltrates 
(Akahoshi et al., 2008; Hamelet et al., 2007; Namekata et al., 2004). The Cth-/- mutant mice 
were generated thorough exons 1 to 6 being replaced with a LacZ and neomycin selection 
cassette (Ishii et al., 2004). The Cth-/- mice have a milder phenotype compared to the Cbs-/- 
mice, the Cth-/- mice have a slight retard in growth, but homozygotes can reach adulthood and 
breed. The Cth-/- mice are normally used as a cystathionemia/cystathionuria model. The Cth-/- 
mice develop hypertension and have an impaired endothelium derived vasorelaxation capacity, 
are very sensitive to oxidative stress, and have lower taurine levels. When fed with low cysteine 
in diet, the Cth-/- mice exhibit acute skeletal muscle atrophy (Ishii et al., 2010; Ishii et al., 2004; 
Wang et al., 2013). 
 
8.3.9 Endogenous levels of hydrogen sulfide in health and disease 
 
A role for H2S in health and disease is supported by the correlations found between the 
plasma/tissue levels of H2S/sulfane sulfur or H2S generating enzymes and the progression of 
diseases such as insulin resistance, hypertension, hyperhomocysteinemia, diabetes, exacerbated 
cardiac injury following ischemia-reperfusion injury, cirrhosis, Alzheimer-disease, progression 
of adiposity, chronic kidney disease, gastrointestinal tract irritation, asthma and cancer among 
others (Gu & Zhu, 2011; Predmore et al., 2012). Like in the case of NO and CO, measuring the 
concentrations of a gas with a short half-life that can form complex with other molecules in 
biological samples, is still very challenging. Conventional methods for the determination of 
H2S fall into two categories: measuring “free” H2S or “labile” H2S. An example of the first 
would be a polarographic sensor, and examples of the second would be colorimetric assays, 
gas-chromatography-mass spectrometry and high-performance liquid chromatography. 
Reported values of labile H2S in plasma and blood range between 20 and 30 µM, in contrast to 
polarographic sensors with detection limit near 10 nM. In tissues from rat brain the values of 
free H2S varied from 14 nM to 70 µM (Kajimura et al., 2010). 
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8.3.10 Mechanism of action of hydrogen sulfide 
 
The molecular targets of H2S include enzymes, proteins, transcription factors and membrane 
ion channels (Predmore et al., 2012). 
 
8.3.10.1 Sulfhydration of proteins 
 
The H2S molecule can sulfhydrate different proteins, and sulfhydration can alter protein 
function suggesting sulfhydration as an important physiologic signaling pathway. An example 
would be that H2S can sulfhydrate nuclear factor κ-light-chain-enhancer of activated B cells 
(NFκB) and cause anti-apoptosis actions (Predmore et al., 2012). 
 
8.3.10.2 Interaction with potassium channels  
 
The H2S molecule can stimulate ATP potassium (KATP) channels. The KATP channels contain 
nine cysteines with C43 that lies close to the surface, which is selectively influenced by 
oxidative insults. The mechanism of action of how H2S interacts with KATP channels is not 
completely understood, but it has been reported that H2S can interact with the sulfonylurea 
receptor subunit of the KATP channel with selective cysteine residues located at the extracellular 
loop of the receptor subunit. The activation of KATP channels has been described as the 
molecular basis of H2S-elicited cardiac protection, blood pressure lowering, or insulin release 
inhibition (Wang, 2010). 
 
8.3.10.3 Vasorelaxation 
  
The H2S molecule can relax blood vessels, H2S resembles the principal properties of endothelial 
derived relaxing factor, and it is localized in the endothelial layer of blood vessels. The H2S 
vasorelaxation, reflects hyperpolarization mediated by the opening of KATP channels via the 
sulfhydration at C43. Unlike NO and CO, H2S does not activate guanylate cyclase (Gu & Zhu, 
2011). 
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8.3.10.4 Oxygen sensitive responses 
 
The vessel wall produces H2S, and it has been proposed that H2S is an O2 sensor in both vascular 
and non-vascular smooth muscle as well as a putative chemoreceptor (Olson et al., 2010). 
Catabolism of H2S is mainly through oxidation in the mitochondria; since oxidation depends 
mainly on O2 availability, depending on the concentration of O2 it will affect the total amount 
of biologically active H2S. In agreement with this theory, high O2 concentration correlates with 
low H2S activity and a dilated pulmonary artery. Inversely, low O2 concentrations correlate 
with higher H2S activity and artery contraction. Indeed, H2S has been found to have both 
vasodilatory and vasoconstrictive effects depending on its concentration. It has also been 
reported that O2 can modulate the activity of both Cbs and Cth, which may have an additive 
impact on the H2S mediated vascular response (Kajimura et al., 2010; Olson, 2011; Wang, 
2010). 
 
8.3.10.5 Anti-inflammatory effects 
 
The H2S molecule is thought to have anti-inflammatory effects through action on KATP 
channels, inhibition of activation of NFκB and p38 MAPK, scavenging of oxidants, up 
regulation of intracellular cAMP, and inhibition of caspase-3 cleavage. Considered a powerful 
inhibitor of leukocyte adherence to the vascular endothelium, H2S may obstruct inflammatory 
processes by diminishing the tissue injury induced by neutrophils via induction of apoptosis 
and/or scavenging of neutrophils derived hypochlorous acid. Reactive oxygen species are 
mediators of NFκB activation and this process can be blocked by antioxidants such as GSH and 
cysteine. It has been described that H2S can down-regulate several pro inflammatory cytokines 
including: NFκβ, TNFα, IL-1β, IL-6 and IL-8 (Chen et al., 2009; Predmore et al., 2012; Wallace 
et al., 2012; Zhang et al., 2013) and that it can activate anti-inflammatory chemokines such as 
IL-10 (Wang, 2010). Promotion of tissue repair by H2S is likely due to its vasodilatory 
properties and activation of cyclooxygenase 2 expression and through promotion of 
angiogenesis. Another property of H2S is that can also act as an energy source substituting for 
oxygen mitochondrial respiration, which may contribute significantly to protection and repair 
of tissue injury (Wallace et al., 2012). Other data support that H2S can also be pro-
inflammatory, mostly at high concentrations, promoting formation of pro-inflammatory 
cytokines and chemokines by up-regulation of NFκB of activated B cells or by activating the 
metabolism of substance P (Gadalla & Snyder, 2010; Wallace et al., 2012; Wang, 2010). 
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Figure 4 Anti-inflammatory effects of hydrogen sulfide.  
Illustration of several mechanism of action involved in the anti-inflammatory effects of hydrogen sulfide 
that include inhibition of leukocyte-endothelial cell adhesion, vasodilation, neutrophil apoptosis, 
antioxidant, reduction of NFκB, inhibition of PDE, nociception, repair, and modulation of KATP channels 
(Wallace et al., 2012). 
 
8.3.10.6 Cytoprotective effects  
 
H2S can strongly influence the redox status through different mechanisms, such as increasing 
GSH levels in the cytosol, the mitochondria, and nucleus of the cell, by increasing the 
GSH/GSSG ratio, activating the protective heat-shock proteins, activating the nuclear factor 
(erythroid-derived2)-like 2 (Nrf2) that results in activation of the antioxidant response elements 
of several antioxidant genes. By activating KATP channels, H2S can also have an anti-apoptotic, 
anti-inflammatory and blood-pressure lowering effects. The cytoprotective effects of H2S also 
involves activation of signaling pathways such as Akt pathways (Kimura et al., 2012; Predmore 
et al., 2012). 
 
8.3.10.7 Antioxidant effects  
 
The H2S molecule is capable of quenching free radicals, since HS
- anions have reducing 
chemical properties. The oxidation of HS- by biochemical relevant two-electron oxidants, yields 
hydrogen disulfide which also has oxidizing activity and is capable of regenerating H2S. 
However, since the concentration of H2S and HS
- is very low in blood and tissues, the anti-
oxidative capacity against free radicals is quite limited (Predmore et al., 2012). 
35 
 
A major antioxidant protein in the human body is GSH, and the action of H2S influencing the 
generation of GSH is often described in the literature: (i) H2S enhances the cellular glutamate 
uptake, (ii) H2S- induced increase in the level of gamma-glutamylcysteine synthethase and 
cysteine transporter activity in the cell, (iii) reduction of cystine into cysteine by H2S in the 
extracellular space, and transport of cysteine into cells by the cysteine transporter, (iv) H2S 
stimulation of the nuclear transcription factor Nrf2, which then up regulates GSH synthesis and 
transport, and (v) a decrease in the activity of the enzymes that catabolize GSH (Predmore et 
al., 2012; Wang, 2010). 
 
8.3.11 Interaction with other gasotransmitters 
 
There are many similarities between the three gases NO CO and H2S, at physiological 
concentrations the three of them act as vasodilators, as cytoprotective and anti-inflammatory 
molecules. When it concerns cross talk between NO and H2S, it has been demonstrated that 
H2S can relax SMCs through release of endothelium-derived hyperpolarizing factor and NO 
from the endothelium. H2S can react with NO to form a nitrosothiol and reducing the 
availability of NO to cause SMCs contraction, and through inhibition of eNOS as well as 
reduction in SMCs cAMP concentration (Kajimura et al., 2010; Li et al., 2009). Moreover, the 
group heme binds to the N-terminal portion of Cbs, comprising about 70 amino acids. In its 
ferrous state, this heme binds both CO and NO. The group heme has more affinity to CO than 
to Cbs, therefore CO can inhibit Cbs activity. The powerful influence of CO upon Cbs raises 
the possibility of cross talk between CO and H2S as messenger molecules (Gadalla & Snyder, 
2010). 
 
8.3.12 Effects of hydrogen sulfide in the nervous system 
 
In the brain H2S is produced mainly in the astrocytes. H2S may have a neuro-protectant role, 
since the first recognized sign of Cbs deficiency in humans is mental retardation and 
Alzheimer’s disease (Enokido et al., 2005; Olson, 2011; Robert et al., 2003). It is suggested that 
Cbs plays a crucial role in the development and maintenance of the central nervous system 
(Kimura et al., 2012; Robert et al., 2003). Cbs-deficient patients also suffer other symptoms 
such as seizures, abnormal electroencephalogram, extrapyramidal disturbances and psychiatric 
disorders (Gadalla & Snyder, 2010). In the nervous system H2S has been shown to have 
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protective effects, preventing the activation of neurotoxins, neuron degeneration, neuron 
apoptosis and gliosis in mice (Predmore et al., 2012). 
 
8.3.13 Role of hydrogen sulfide in different lung diseases  
 
The three H2S-generating enzymes are variably expressed in the lung depending on the species: 
Cth and Mpst are widely expressed in bovine pulmonary arterial smooth muscle cells, while 
Cbs has only been found in bovine pulmonary arterial endothelial cells. In humans, both airway 
SMCs and primary fibroblast express Cth and Cbs. In contrast, in mice, both Cth and Cbs were 
found in pulmonary blood vessel SMCs and endothelial cells as well as in airway SMCs (Olson 
et al., 2010; Wang et al., 2011). The role of H2S in different chronic lung disease has been 
recently reviewed by Chen et al. (Chen & Wang, 2012) and it is summarized in Figure 5. In 
chronic obstructive pulmonary disease (COPD), H2S has proven to be an anti-inflammatory and 
bronchi dilatant agent, decreasing the expression of TNFα and IL-8 lung tissue of chronic 
cigarette smoke exposed rats treated with NaHS in comparison to control rats. Similar results 
were found by another group, using a tobacco smoke induced emphysema mouse model, where 
NaHS treatment ameliorated inflammation measured in bronchoalveolar lavage (BAL), 
reduced the increase in right ventricle systolic pressure, the thickness of pulmonary vascular 
walls and right ventricular hypertrophy. The serum levels of H2S COPD patients varied 
depending on stage and tobacco exposure and further studies are needed to use it as a marker 
(Chen et al., 2005). In the case of asthma, lower levels of H2S were found in asthmatic patients, 
related negatively to sputum counts and positively to forced expiratory volume capacities. In 
an experiment with ovalbumin treated rats, exogenous administration of NaHS increased peak 
expiratory flow, decreased goblet cell hyperplasia and collagen deposition score, decreased 
total cells in BAL and influx of eosinophils and neutrophils (Benetti et al., 2013; Chen & Wang, 
2012; Chen et al., 2009). Moreover, the Cth-/- mice when challenged with ovalbumin, had 
worsen airway inflammation and elevated cytokines such as IL-5 and IL-13 in BAL when 
compared to wild type littermates, and interestingly, recovery treatment with NaHS supplement 
rescued the  Cth-/- mice from the aggravated pathological picture (Zhang et al., 2013). In 
pulmonary fibrosis, NaHS has been reported to decrease pulmonary fibrosis caused by 
bleomycin, decreasing lung hydroxyproline content and malondialdehyde. The authors 
speculated about an anti-oxidative effect of NaHS against lipid peroxidation produced by ROS. 
Treatment with NaHS has been proven to arrest cultured human fibroblasts in the G1 phase of 
the cell cycle, and trigger them into apoptosis. Furthermore, treatment with H2S decreased 
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pSmad2/3 phosphorylation in A549 cultured cells stimulated with TGF-β1, and prevented 
epithelial to mesenchymal transition (Chen & Wang, 2012; Fang et al., 2009). Finally, H2S has 
demonstrated a regenerative effect in two different models of acute lung injury, in a mouse 
model of lipopolysaccharide-induced lung injury, it improved lung structure in histological 
examination and prevented cytokine release in BAL fluid, clarified in Figure 6 (Faller et al., 
2012). In a mechanical ventilation rat model, NaHS treatment improved inflammation and 
oxygenation in comparison to the control group (Aslami et al., 2010). 
 
 
 
Figure 5 Mechanism of action of H2S in chronic lung diseases. 
Several mechanism of action of H2S: Inhibition of airway smooth muscle cell proliferation, inhibition 
of bronchoconstriction, modulation of lung fibroblast differentiation, inhibition of epithelial to 
mesenchymal transition, modulation of hypoxic pulmonary vasoconstriction, neurogenic inflammation 
and inhibition of oxidative stress. Glutathione reduced form (GSH), glutathione oxidized form (GSSG), 
substance P (SP), calcitonin gene-related peptide (CGRP), transforming growth factor beta (TGF-β) 
(Chen & Wang, 2012). 
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Figure 6 Effect of lipopolysaccharide induced acute lung injury and effect of H2S inhalation on lung 
structure.  
Control mice treated with phosphate buffer saline intranasal and room air (A), 80 ppm hydrogen sulfide 
(H2S) for 6 h (B), lipopolysaccharide (LPS) treated mice and room air (C) and LPS and 80 ppm H2S 
treated mice for 6 h (D). Sections stained with hematoxylin and eosin (Faller et al., 2012).  
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9 Hypothesis and aims 
 
Bronchopulmonary dysplasia is a dangerous complication of the premature newborn. There is 
a lot of effort in the scientific community to unravel the disease mechanisms and identify 
therapies that could improve lung growth from these infants. It is thought that anti-
inflammatory, cytoprotective, antioxidant and vascular protective approaches, which are meant 
to be properties of H2S, could be beneficial treating BPD.   
 
In this context, it was also observed that the expression levels of the H2S generating enzymes 
Cbs and Cth, changed over the course of normal mouse late lung development. 
 
Thus it was hypothesized that: 
In the BPD model H2S can be used as a potential treatment, due to cytoprotective, anti-
inflammatory, antioxidant and pulmonary vasodilatory properties and that Cbs and Cth play a 
role in normal late lung development. 
 
Hence, the aims of the study were: 
(a) Using a hyperoxia BPD mouse model to expose the animals either to vehicle or to a H2S 
donor, and study the effect of the treatment on lung structure during normal and aberrant late 
lung development. 
(b) In the case of improved in alveolarization in (a), to study the possible mechanisms of action 
that would impact lung development. 
(c) To study the role of Cbs and Cth during mouse late lung development. 
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10 Materials and methods 
 
 Equipment and software 
 
Equipment and software      Manufacturer 
Adobe Photoshop Software     Adobe Systems, USA 
Autoclave       Systec, Germany 
BD FACS CantoTM flow cytometer    BD Biosciences, USA 
Cell culture incubator HERAcell 150i   Thermo Scientific, USA 
Cell culture plates (6-, 24-, 96- well plates)   Greiner Bio-One, Germany 
Cell culture flasks (75 ml)     Greiner Bio-One, Germany 
Cell counter, Countess®     Invitrogen, UK 
Corning® Costar® cell culture plates   Sigma-Aldrich, Germany 
Culture-insert μ-dish©      Ibidi® cells in focus, USA 
Electrophoresis chambers      Bio-Rad, USA 
FACSDivaTM software      BD Biosciences, USA 
Filter Tip FT: 10, 20, 100, 200, 1000    Greiner Bio-One, Germany 
Freezer -20 °C       Bosch, Germany 
Freezer -40 °C       Kryotec, Germany 
Freezer -80 °C       Heraeus, Germany 
Fridge +4 °C        Bosch, Germany 
Gel blotting paper 70 x 100 mm     Bioscience, Germany 
Hood with laminar flow     Thermo Scientific, USA 
Image J Software       NIH, USA 
Image QuantTM LAS4000     GE Healthcare, UK   
Microscope (light, phase contrast, fluorescent,   
Laser-capture micro dissection, confocal)   Leica, Germany  
Microtome (paraffin-, plastic-, cryo- sections)  Leica, Germany 
Mini spin centrifuge       Eppendorf, Germany 
Multifuge centrifuge, 3 s-R      Heraeus, Germany 
NanoDrop® ND 1000     Peqlab, Germany 
NanoZoomer-XR C12000 Digital slide scanner   Hamamatsu, Japan 
PCR-thermo cycler: peqSTAR     Peqlab, Germany 
PCR-tubes (0.2 ml)       Applied Biosystems, USA 
41 
 
Petri dishes       Eppendorf, Germany 
Pipetboy        Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000    Gilson, France 
Precellys® 24 Homogenizer     Peqlab, Germany  
QWin software      Leica, Germany 
Single-use syringe       Braun, Germany 
Reaction tubes: 0.5, 1.5, 2 ml     Eppendorf, Germany 
Stepanizer© stereology software    Tschanz, Switzerland 
StepOnePlusTM Real-Time PCR    Applied Biosystem, Germany 
Test tubes: 15, 50 ml       BD Biosciences, USA 
Trans blot transfer membrane (0.2 μm)    Bio-Rad, USA 
Visiopharm NewCastTM computer-assisted  
stereology system (VIS 4.5.3)    Visiopharm, Denmark 
VersaMax Micro plate reader     Molecular Devices, Germany 
Vortex machine       Eppendorf, Germany 
Vacuum centrifuge       Eppendorf, Germany 
Western blot chambers, Mini Trans-Blot    Bio-Rad, USA 
Western blot chambers, Mini-Protean 3 Cell   Bio-Rad, USA 
WIMASIS Software WimTube    Wimasis GmbH, Deutschland 
 
 Reagents  
 
Reagents       Manufacturer 
Acetone        Roth, Germany 
Acrylamide solution, Rotiphorese Gel 30    Roth, Germany 
Agar-agar       Merck, Germany 
Agarose        Invitrogen, UK 
Accutase       Invitrogen, UK 
AlexaFluor® 488 Annexin V/Dead  
Cell Apoptosis Kit      Invitrogen, UK   
BD BioCoatTM BD MatrigelTM plate     Becton Dickinson, USA 
Bioxytech© GSH/GSSG kit     OxisResearch, USA 
Bovine serum albumin     Sigma-Aldrich, Germany 
Bromophenol blue       Sigma-Aldrich, Germany 
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Ceramic beads       PeqLab, Germany 
CompleteTM Protease inhibitor    Roche, Germany 
Diaminobenzidine      Vector Laboratories, USA 
DNA Ladder (1 kb, 100 bp)      Promega, USA 
DNase I       Serva, Germany 
DTT        Promega, USA 
Dulbecco’s modified Eagle’s medium (DMEM)  Gibco BRL, Germany 
Dulbecco´s phosphate buffered saline 10×    PAA Laboratories, Austria 
Dulbecco´s phosphate buffered saline 1×    PAA Laboratories, Austria 
Ethylendinitrilo-N, N, Nʹ,Nʹtetra-acetic-acid (EDTA)  Promega, USA 
Ethanol absolute       Riedel-de Haen, Germany 
ECL Plus Western Blotting Detection System Amersham  Bioscience, UK 
ELISA kit (TNFα, IL-10)     BD Biosciences, USA 
ELISA kit (IL-6, I-1β)     Qiagen, Germany 
Fetal bovine serum      Gibco BRL, Germany 
Ethidium bromide       Roth, Germany 
Fe-Hematoxylin Weigert     Waldeck, Germany 
Fuchsin-Resorcin      Waldeck, Germany 
Giemsa solution      Merck, Germany 
Glibenclamide       Tocris Bioscience, UK 
Glutaraldehyde      Sigma-Aldrich, Germany 
Glycine        Roth, Germany 
GoTaq® DNA polymerase     Promega, USA 
GYY4137       Enzo, USA 
Hanks’ balanced salt solution (HBSS)   Euro lone, Italy 
HEPES buffer       Sigma-Aldrich, Germany 
Hydrogen peroxide      Sigma, Germany 
iScript™ cDNA Synthesis Kit    BioRad, USA 
ImmPRESS kit      Vector Laboratories, USA 
LipofectamineTM 2000     Invitrogen, UK 
May-Grünwald solution     Merck, Germany 
β-mercaptoethanol       Sigma-Aldrich, Germany 
Meta-phosphoric acid      Sigma-Aldrich, Germany 
Methanol        Fluka, Germany 
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Methyl green       Sigma, Germany 
MES buffer       OxisResearch, USA 
MM HRP polymer      Zytomed Systems, Germany 
MuLV reverse transcriptase     Applied Biosystems, Germany 
NaHS        Sigma-Aldrich, Germany 
Nuclease free water      Ambion, USA 
Oligo(dT) primer       Promega, USA 
Opti-MEM® Medium      Gibco BRL, Germany 
Osmium tetroxide      Carl Roth, Germany  
Penicillin/streptomycin     GE Healthcare, UK 
PCR Nucleotide Mix       Promega, USA 
PfuUltra™ High-Fidelity DNA polymerase   Thermo Scientific, Germany 
Platinum® SYBR® Green qPCR SuperMix UDG Kit Invitrogen, UK 
Propidium iodide      Invitrogen, UK 
Proteinase K       Promega, USA 
2-Propanol        Merck, Germany 
Quick StartTM Bradford Dye Reagent    Bio-Rad, USA 
Paraformaldehyde      Sigma-Aldrich, Germany 
PeqGold total RNA kit      Peqlab, Germany 
Pertex mounting media     Leica, Germany 
RNAase Inhibitor       Applied Biosystems, USA 
RNeasy Midi Kit       Qiagen, Germany 
Rodent block M      Zytomed Systems, Germany 
Roti®-Histol       Roth, Germany 
Scott’s tap water substitute     Leica, Germany 
SDS 10% solution      Promega, USA 
Sodium cacodylate      Serva, Germany 
Sodium vanadate      Sigma-Aldrich, Germany 
Staurosporine        Sigma-Aldrich, Germany 
SuperSignal® West Pico Chemi luminescent Substrate  Thermo Scientific, USA 
Technovit 7100      Heareus Kulzer, Germany 
Tissue Tek®       Sakura, Japan 
Triethanolamine       Sigma-Aldrich, Germany  
Tris         Roth, Germany 
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Trypsin       Invitrogen, UK 
Tween® 20        Sigma-Aldrich, Germany 
Uranyl acetate       Serva, Germany 
Van Gieson stain      Applichem, Germany 
Vector Vip substrate kit     Vector laboratories, USA  
Xylol        Roth, Germany 
 
 Cell lines 
 
MLE-12; CRL-2110      ATCC, USA 
HPAEC; CC-2530      Invitrogen, USA 
 
 Primer list 
 
Table 2 Primers for RT-PCR analysis 
Gene Sequence (5´3´) 
Cth m.m. Forward primer   GGGATGGCGGTGGCTCGTTT 
Cth m.m. Reverse primer   AGCCCGAGCACTGGCGTTTG 
Cbs m.m. Forward primer   TGAACCAGACGGAGCAAACA 
Cbs m.m. Reverse primer   CCAGGACTGTCGGGATGAAG 
Polymerase r 2a m.m. Forward primer   CTAAGGGGCAGCCAAAGAAAC 
Polymerase r 2a m.m. Reverse primer   CCATTCAGCATACAACTCTAGGC 
m.m. = Mus musculus. 
 
Table 3 Primers for genotyping 
Gene Sequence (5´3´) 
Cbs m.m. Forward primer common GATTGCTTGCCTCCCTACTG  
Cbs m.m. Reverse primer wild type AGCCAACTTAGCCCTTACCC  
Cbs m.m. Reverse primer mutant CGTGCAATCCATCTTGTTCA  
Cth m.m. Forward primer common TGCCGACCAATAAGCAGGGC 
Cth m.m. Reverse primer wild type CCGAGGACTGGCCCGGGAAGT 
Cth m.m. Reverse primer mutant CCAGACCGGCAACGAAAATCA 
m.m. = Mus musculus. 
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 Antibodies 
 
Table 4 Antibodies 
Name Catalogue 
number 
Dilution Manufacturer 
α–smooth muscle actin A-2547 1:900 Sigma-Aldrich, Germany 
α–smooth muscle actin-Cy3 C6198 1:400 Sigma-Aldrich, Germany 
Akt pan 11E7 4685 1:1000 Cell Signaling, USA 
βactin 4970 1:3000 Cell Signaling, USA 
CBS  LS-C154538 1:1000; 1:10 (IF) LS Bioscience, USA 
CD 31 Ab28364 1:500 Abcam, UK 
CTH HPA023300 1:600; 1:100 (IF) Sigma-Aldrich, Germany 
DAB SK4100 1:100 Vector Laboratories, USA 
DAPI D21400 1:100 Invitrogen, USA 
FITC-conjugated mouse IgG1,  
isotype control 
551954 1:1000 BD Biosciences, USA 
Goat anti-mouse IgM 31440 1:3000 Thermo Scientific, USA 
Goat anti-mouse IgG (H+L) 
Alexa Fluor® 568  
A-11031 1:1000 Life Technologies, Germany 
Goat anti-rabbit IgG 31460 1:3000 Thermo Scientific, USA 
Goat anti-rabbit IgG (H+L) Alexa 
Fluor® 488 
A-11034 1:1000 Life Technologies, Germany 
IgG anti mouse Alexa Fluor A568 A-11031 1:1000 Molecular probes, USA 
IgG anti rabbit Alexa Fluor A448 A-11034 1:1000 Molecular probes, USA 
IgG1 PETexas Red® conjugate MG117 1:1000 Invitrogen, USA 
Mouse IgG isotype control 10400C 1:400 Invitrogen, USA 
Anti-rabbit IgG-HRPO  MP-7401 1:100 Immpress Vector Laboratories, 
USA 
Anti-mouse IgG-HRPO MM620 1:900 Biocare Medical USA 
Propidium iodide V13241 1:1000 Sigma-Aldrich, Germany 
phospho-Akt Ser473 4060 1:500 Cell Signaling, USA 
Rabbit IgG isotype control 2729 1:100, 1:10 Cell signaling, USA 
von Willebrand factor A0082 1:900 (IHC); 
1:100 (IF) 
Dako, Germany 
IHC=Immunohistochemistry; IF=Immunofluorescence. 
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 siRNA 
 
For the assessment of the role of Cbs and Cth in angiogenesis in vitro, HPAEC cells were 
transfected with a mixture of opti-mem (Opti-MEM® Medium, Gibco BRL, Germany), 
lipofectamine (LipofectamineTM 2000, Invitrogen, UK) and either with scrambled (200 nM; 
Santa Cruz Technology, USA, sc-37007) or siRNA CBS (200 nM; Santa Cruz Technology, 
USA, sc-60335) and cultured during 6 h in a humidified 5% (vol/vol) CO2 atmosphere. After 
that, the transfection media was changed to DMEM media supplemented with LVES 2% 
(vol/vol), and cells were cultured during 48 h prior to detachment with Accutase and counted 
and re-seeded for the endothelial tube-formation assay. 
Several attempts with different CTH siRNA (Santa Cruz Technology, USA) were tested but not 
successful. Instead, the CTH inhibitor propargylglycine (PAG) was used (1 mM or 3 mM during 
24 h).  
 
 Mouse model of bronchopulmonary dysplasia 
 
Exposure to normobaric hyperoxia (85% O2) induced an arrest in alveolarization to mouse pups, 
as described previously (Alejandre-Alcazar et al., 2008). This model has formerly been 
characterized in our research group (Alejandre-Alcazar et al., 2008) and other groups 
(Buczynski et al., 2013; Fernandez-Gonzalez et al., 2012), where a pronounced arrest of lung 
development is seen in response to hyperoxia exposure. Both groups, the normoxia (21% O2) 
and the hyperoxia (85% O2) group, were further divided into two groups, treated with daily 
intraperitoneal (i.p.) injections of either water (used as vehicle control) or with GYY4137 a 
slow-release H2S donor  (Li et al., 2008), at a dose of 50 mg/kg dissolved in water, for nine 
days. To minimize oxygen toxicity and to prevent potential cofounders of milk production 
caused by changes in inspired oxygen levels, nursing dams were rotated every 24 h between 
normoxia and hyperoxia conditions. Dams and mouse pups received food ad libitum and were 
kept on 12 h light-dark cycle. Mouse pups were sacrificed on the tenth day of life, by euthanasia 
with an overdose of isofluorane, followed by thoracotomy and lung extraction. All animal 
experiments and procedures were approved by the local authorities, the Regierungspräsidium 
Darmstadt (approval B2/327). 
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 Lung processing 
 
Isolation of lungs was processed differently depending on the posterior analysis. The lungs from 
transgenic and wild-type mice were harvested on different postnatal days depending on the 
experiment. Lungs were embedded in glycol methacrylate for stereological analysis; lungs were 
embedded in paraffin for immunohistochemistry and immunofluorescence analysis, lungs were 
cryopreserved for laser-capture micro dissection analysis, and lungs were frozen in liquid 
nitrogen and stored in -80 ºC for RNA and protein isolation analysis. 
 
 Design-based stereology 
 
The methods used in this study were based on newly published American Thoracic 
Society/European Respiratory Society recommendations for quantitative evaluation of lung 
structure (Hsia et al., 2010). Mouse pup lungs were instillation-fixed via a tracheal cannula at 
a hydrostatic pressure of 20 cm H2O with 1.5% (wt/vol) glutaraldehyde, 1.5% (wt/vol) 
paraformaldehyde, in 150 mM HEPES pH7.4, at 4°C for 24 h as defined previously (Knudsen 
et al., 2007). Lung tissue blocks were collected via systematic uniform random (SUR) sampling 
for stereological analysis (Ochs, 2006; Weibel et al., 2007). Whole lungs were embedded in 
agar and cut into pieces of 2 mm thickness. Using the Stepanizer© stereology software (Tschanz 
et al., 2011), the total volume of the lungs was measured by Cavalieri’s principle. Because the 
neonatal lungs are very small in size, whole lungs were treated with 0.1 M sodium cacodylate, 
1% (wt/vol) osmium tetroxide and 4.5% (wt/vol) uranyl acetate, and embedded in glycol 
methacrylate. Each tissue block was cut into sections of 2 μm, and every first and third section 
of a consecutive series of sections was stained with Richardson’s stain. The NanoZoomerXR 
C12000 Digital slide scanner was used to scan all slides. The SUR sampling was continued 
throughout all steps of microscopic analysis, as described previously for adult lungs 
(Fehrenbach et al., 2008; Knudsen et al., 2013; Muhlfeld & Ochs, 2013; Ochs & Muhlfeld, 
2013; Schneider & Ochs, 2013; Voswinckel et al., 2004). The Visiopharm NewCastTM 
computer-assisted stereology system was employed to do all investigations. Structural analyses 
included the determination of alveolar number, surface area, total alveolar septal volume, mean 
linear intercept (MLI), and mean alveolar septal wall thickness. The number of alveoli was 
counted using a physical disector (disector height 4 μm). Surface densities and alveolar septal 
volumes were determined by intersection and point counting, respectively, and were multiplied 
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by the reference volume (total lung volume) to get absolute values. The microtome was 
calibrated prior to use. An example of the tools used for the stereological analysis is illustrated 
in Fig. 7. The stereological analysis was applied to the first experiment, where two control 
groups of mice, which received daily injections (i.p.) of vehicle alone (water) from the first day 
of life (P1), until the tenth day of life (P10), that were exposed either to 21% O2, or to 85% O2. 
Moreover, two experimental groups were also evaluated, which received daily injections (i.p.) 
of the slow-release H2S donor molecule GYY4137 (50 mg/kg body mass, in H2O), from the 
first day of life (P1), until the tenth day of life (P10), that were exposed either to 21% O2, or to 
85% O2. The same type of analysis was also applied to the second experiment to study the 
course of normal late lung development on two different time points: On P7.5 and P14.5, either 
wild type mice, Cbs-/- or Cth-/- mice. The coefficient of error (CE), the coefficient of variation 
(CV) and the squared ratio between both (CE2/CV2) were measured for each stereological 
parameter to be <0.5 to validate the precision of the measurements. 
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Figure 7 Example of stereological analysis of neonatal mouse lungs exposed to either 21% O2 or 85% 
O2 pressure, fixed via the airways, and stained with Richardson’s stain.  
A, point grid superimposed randomly into a field of view of a virtual Nanozoomer-scanned lung tissue 
section from a mouse pup at P10 exposed to 21% O2 for the first 10 days of life (20× magnification). 
The counted points need to fall on the reference space (i.e. parenchyma) to be counted, and were 
subdivided into different categories, namely alveolar air spaces (A; alveoli and ducts), capillaries (C) 
and septal wall (S). B, representation of same situation as (A) but with a line grid. Each line was 
associated with two points that when fell on the reference space (i.e. parenchyma) were counted. The 
length of the test-line is approximately 110 µm. Intersection of the test lines with the alveolar surface 
were also counted (green crosses). C, the same situation as (A) is represented, but in a lung from a mouse 
pup exposed to 85% O2. D, The same situation as in (B) is represented, but in a lung from a mouse pup 
exposed to 85% O2. E and F, fields of view with a counting frame superimposed over the image of 
virtual Nanozoomer-scanned slides at 40× magnification from the first and third histological sections in 
a consecutive series of serial sections for the alveolar count, each of 2 µm thickness (disector height, 4 
µm). An alveolar bridge (B) is counted if an alveolar opening is open in one section (E) and closed in 
the other section (F) or vice versa. In this illustration (E) is considered the reference section, and (F) the 
look-up section. G and H, representation of the same situation as in (E) and (F), respectively, but in a 
lung from a hyperoxia-exposed mouse pup (Madurga et al., 2014). 
 
 Bronchoalveolar lavage  
 
Bronchoalveolar lavage was performed for each mouse pup (four groups; n=6 per group), and 
cytoslides with lung leukocytes were stained for May-Grünwald Giemsa following the 
protocols described in (Regal, 2004). 
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 Immunofluorescence staining of mouse lung sections 
 
Paraffin-embedded lung tissue sections (3 m) were stained as described previously (Alejandre-
Alcazar et al., 2007) to localize Cbs and Cth in the lung. Serial sections were stained to ease 
antigen localization since co-staining of the same section was not successful. Shortly, paraffin 
sections were warmed for 20 min at 65 ºC, de-paraffinized with a series of Roti®-Histol (Roth), 
100% (vol/vol), 90% (vol/vol) and 70% (vol/vol) ethanol, and processed for antigen-retrieval, 
for which different protocols were applied depending on the antigen. For von Willebrand factor 
(vWF), antigen-retrieval was by boiling in 10 mM Tris-Cl, pH 10.0 for 10 min, followed by a 
trypsin digestion 37 ºC for 10 min, while for -smooth muscle actin (SMA), antigen-retrieval 
was by boiling in citrate buffer (10 mM, pH 6.0) 10 min. Slides were cooled and washed with 
dH2O and with 1×PBS. Sections were incubated with blocking buffer, and with the appropriate 
primary antibodies overnight at 4 ºC. The antibodies employed were rabbit anti-human Cbs, 
rabbit anti-human Cth, rabbit anti-human vWF and mouse anti-human SMA-Cy3 conjugate. 
For unconjugated primary antibodies, the next secondary antibodies were employed: goat anti-
mouse IgG (H+L)-Alexa Fluor® 568 conjugate and goat anti-rabbit IgG (H+L) -Alexa Fluor® 
488 conjugate. As IgG control the next non-immune antibodies were used at the concentration 
as the corresponding primary antibody: mouse IgG and rabbit IgG. Nuclear staining was 
performed with 4,6-diamidino-2-phenylindole (DAPI). Images were analyzed with a Leica 
DFC 360FX microscope.  
 
 Determination of medial wall thickness index and degree of 
vessel muscularization 
 
The index of medial wall thickness (MWT) and the degree of muscularization of small (internal 
diameter 20-70 m), medium (internal diameter 70-150 m), and large (internal diameter >150 
m) pulmonary vessels were evaluated in paraffin-embedded lung sections (3 m), exactly as 
described previously (Dahal et al., 2010; Malczyk et al., 2013). The methodology used for this 
study gives a general idea of whether changes in the MWT and vessel muscularization occur. 
On the other hand, this methodology does not follow design-based stereological principles, and 
there was no SUR sampling of tissue samples. MWT was indexed as a percentage of the vessel 
diameter, using the formula MWT (%) = 100 × [(2×medial wall thickness)/(outer vessel 
diameter)] (Ambalavanan, et al. 2005; Rabinovitch et al., 1979). Staining of sections was 
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performed with van Gieson’s stain for MWT determination, or by immunohistochemistry for 
SMA and vWF for muscularization assessment. The antibodies rabbit anti-human vWF and 
mouse anti-human SMA were used. As secondary antibodies, anti-rabbit IgG-HRPO 
conjugate and anti-mouse IgG-HRPO conjugate were employed. 
 
 Assessment of vascular supply in lung sections 
 
Paraffin-embedded lung tissue sections (3 m) were stained for vWF using rabbit anti-human 
vWF. Then, sections were rinsed with 1×PBS and incubated with an anti-rabbit IgG HRPO 
conjugate. Immune complexes were visualized with 3,3-diaminobenzidine (DAB) and 
counterstained with methyl green. After that, sections were dehydrated in 96% (vol/vol) 
ethanol, isopropanol and xylol, and then mounted. Sections were analyzed by light microscopy 
using a Leica microscope (CTR6000) with the QWin software. All images were taken at 20× 
magnification. The cross-sections of vWf-positive vessels were counted in four representative 
high-power fields per animal, a parameter that depends on the length of the vascular system. 
As with the MWT index and vessel muscularization methodology described above, this 
methodology does not follow design-based stereological principles, and there was no SUR 
sampling of tissue samples.  
 
 Endothelial tube-formation assay 
 
Human pulmonary artery endothelial cells (HPAEC; Lonza, Walkersville, MA, U.S.A.; 
#CC-2530) were transfected to determine endothelial tube formation capacity. Cells were 
transfected either with siRNA directed against human CBS (200 nM; Santa Cruz, Heidelberg, 
Germany; #sc-60335) or with scrambled siRNA (200 nM; Santa Cruz, Heidelberg, Germany; 
#sc-37007), or the CTH inhibitor PAG 1 mM or 3 mM during 24 h, or after treatment with the 
slow release H2S donor GYY4137 (100 µM during 24 h) or vehicle alone  (DMEM Media 200 
with LVES supplement 2% (vol/vol); Gibco, Karlsruhe, Germany; #ATCC 30-2002 and 
#A14608-01, respectively). The HPAEC were seeded (100.000 cells/well) into Matrigel-coated 
wells of a 24-well plate (BD BioCoatTM BD MatrigelTM plate; Becton Dickinson, Heidelberg, 
Germany; #3554480). Prior to loading on the Matrigel plate, HPAEC had been transfected with 
siRNA for 48 h, detached with Accutase and cells were counted prior to re-seeding. Total tube 
length and numbers of tubes were measured using a Leica CTR6000 microscope, with the aid 
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of WimTube software (Wimasis, Munich, Germany). Cell viability in response to siRNA, 
GYY4137 and PAG treatment was calculated using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT).  
 
 Primary ATII cells and cell-lines 
 
Primary mouse lung alveolar type II (ATII) cells were isolated from the lungs of adult C57Bl/6J 
mice as described previously (Alejandre-Alcazar et al., 2007; Morty et al., 2007). The ATII 
cells were cultured on an air/liquid interface for three days after isolation and used on day three 
after isolation. The ATII cells were cultured in DMEM supplemented with 10% (vol/vol) FBS 
and 1% (wt/vol) penicillin/streptomycin in a humidified 5% (vol/vol) CO2 atmosphere. 
Transformed mouse lung epithelial cells (MLE-12; ATCC, USA;# CRL-2110) were cultured 
in DMEM supplemented with 10% (vol/vol) FBS in six-well tissue culture plates, as described 
above. Equally primary mouse lung ATII cells and MLE-12 cells were maintained in starvation 
media (DMEM without FBS) for 6 h and treated with NaHS (100 μM) dissolved in DMEM for 
10, 15, 20, 30 and 60 min. 
 
 ATII cell isolation and staining for flow cytometry 
 
Primary mouse lung ATII cells were treated either with vehicle (DMEM, supplemented with 
10% (vol/vol) FBS), NaHS (100 μM) for 24 h, or with staurosporine 0.5 μM for 1.5 h. Cells 
were detached with Accutase and proceeded according to established protocols for the detection 
of apoptosis by flow cytometry (Rieger et al., 2011). Shortly, cell staining with performed using 
an AlexaFluor® 488 Annexin V/Dead Cell Apoptosis Kit, or with FITC conjugated mouse 
IgG1, isotype control, mouse IgG1 PETexas Red
® conjugate. Using a BD FACS CantoTM flow 
cytometer, 10.000 ATII cells/sample were analyzed (n=5 per group). The samples were 
analyzed with FACSDiva version 6.1.3.    
 
 ATII cell isolation and staining for immunofluorescence 
 
Primary mouse lung ATII cells were treated either with vehicle (DMEM, supplemented with 
10% (vol/vol) FBS), the fast release H2S donor NaHS (100 μM) for 24 h, or with staurosporine 
0.5 μM for 1.5 h. Cells were stained with propidium iodide and DAPI and analyzed with a Leica 
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microscope (DFC 360FX). Representative images of every sample were taken at 10× 
magnification, and >300 cells were counted per sample, (n=4 per group). 
 
 RNA isolation and cDNA synthesis for RT-PCR analysis 
 
Either mouse lung homogenates or cells (both primary cells and cell lines) were homogenized 
in RNA lysis buffer in Precellys® 24-Dual Homogenisator using 1.4 mm ceramic beads to 
disrupt tissue (n=4-6). The RNA isolation was performed using a peqGOLD Total RNA Kit 
from Peqlab following the manufacturer´s instructions. The RNA concentration was measured 
using a Nanodrop Spectophotometer. Taking 1000 ng of total RNA, cDNA was obtained using 
a MuLV reverse transcriptase from Applied Biosystems, and RNAse free water.  
 
 Laser-capture micro dissection 
 
Frozen cryosections from wild type mouse at P7.5 and P14.5 (n=4 per group) were cut in 10 
µm thickness using a Leica microtome (RM2255). The sections were afterwards treated with a 
series of ethanol (70%, 90%, and 99% (vol/vol) ethanol), washed with RNAse free water, and 
with Scott’s tap water, and finally stained with Hematoxylin. Compartmentalization of tissue 
was taken from different samples, falling into the categories: Parenchyma, airway, and lung 
vascular compartment, using a Leica laser micro dissection system (LMD 6500). As pulmonary 
arteries and pulmonary veins are difficult to discriminate in unstained cryosections, all vessels 
were harvested together, and no discrimination between arteries and veins has been attempted. 
Samples were collected in RLT-buffer that contained β-mercaptoethanol. Isolation of RNA was 
performed using a PeqGold total RNA kit isolation kit following the manufacturer’s indications. 
Synthesis of cDNA was fulfilled using iScriptTM cDNA Synthesis Kit, from BioRAD, following 
the manual’s instructions. 
 
 RT-PCR analysis 
 
Quantitative changes in mRNA expression of genes was determined using a quantitative real 
time PCR method. The RT-PCR analysis were performed using a Platinum® SYBR® Green 
qPCR SuperMix UDG Kit (Invitrogen) and a StepOnePlus PCR Machine (Applied 
Biosystems). The primers were synthesized in Eurofins MWG Operon. As a house-keeping 
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gene for mouse samples, the gene POL2RA was used as a reference gene. The table of primer 
sequences can be found in Table 2. 
 
 Protein isolation for immunoblots 
 
Cells were homogenized by scraping in lysis buffer: 20 mM Tris-Cl, 150 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1% (vol/vol) NP-40, 1 mM sodium ortho-vanadate and 1× CompleteTM 
protease inhibitor cocktail. Proteins from mouse lung tissue were homogenized in lysis buffer 
by disruption in Precellys® 24-Dual Homogenisator using 1.4 mm ceramic beads to disrupt 
tissue (n=3-8 per group). Protein concentration was determined by Bradford assay. 
 
 Protein expression analysis 
  
Immunoblotting was performed as described previously, (Alejandre-Alcazar et al., 2007; Morty 
et al., 2007), using the following primary antibodies: anti-phospho-Akt, anti-Akt, anti-Cbs, anti-
Cth, anti-CD31 and anti β-actin. Immune complexes were detected with a secondary antibody 
anti-rabbit IgG horseradish peroxidase conjugate, employing enhanced chemiluminescence. 
Densitometric analysis of immunoblot bands was determined using the Multi Gauge MFC 
Application version 3.0.0.0. 
 
 Wound healing assay  
 
The ATII cells were cultured in in DMEM supplemented with 10% (vol/vol) FBS on an ibidi 
culture-insert μ-dish© that contained a grid, until a confluent monolayer was formed. The cells 
were maintained for 24 h in starvation media (DMEM without FBS supplementation) prior to 
remove the insert of the grid. Once the insert was removed, it left a wound in the ATII cell 
monloayer. Next, the cells were treated either with DMEM, NaHS (100 μM) dissolved in 
DMEM, glibenclamide (10 μM) dissolved in DMEM, or with glibenclamide (10 μM) dissolved 
in DMEM, for 30 min, followed by the addition of NaHS (100 μM; final concentration). Three 
representative images of every sample were taken at 0, 4, 8, 12 and 24 h at 5× magnification 
(n=6 per group), with a Leica (DMI3000B) microscope. Using Image J Software and Adobe 
Photoshop CS5 Software, the wound distance and the number of cells that migrated over time 
were measured. 
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 ELISA 
 
Proteins from mouse lung tissue were homogenized in MES buffer by disruption in a Precellys® 
24-Dual Homogenisator using 1.4 mm ceramic beads to disrupt tissue (n=5-6 per group). 
Protein concentration was determined using Bradford assay. Using 5 mg of lung extract 
proteins, mouse ELISA kits R&D and Qiagen were used following the manufacturer´s 
instructions to measure changes in the protein abundance of IL-10, IL-6, IL-1β and tumor 
necrosis factor (TNFα). ELISA measurements were performed in a VersaMAX microplate 
spectrophotometer. 
 
 Glutathione assay 
 
Proteins from mouse lung tissue were homogenized in gluthatione assay buffer by disruption 
in Precellys® 24-Dual Homogenisator using 1.4 mm ceramic beads to disrupt tissue (n=8 per 
group). Protein concentration was measured using the Bradford assay. Proteins were treated 
with 4 M triethanolamine and 5% (wt/vol) meta-phosphoric acid. Using a 
Bioxytech®GSH/GSSG kit following the manufacturer’s instructions, the ratio of reduced 
glutathione (GSH) was compared to oxidized glutathione (GSSG). 
 
 Microarray analyses 
 
Primary mouse ATII cells were either treated with vehicle (DMEM, supplemented with 10% 
(vol/vol) FBS) or GYY4137 (100 μM; dissolved in DMEM, supplemented with 10% (vol/vol) 
FBS) for 24 h. In another set of experiments primary mouse ATII cells were either treated with 
vehicle (DMEM, supplemented with 10% (vol/vol) FBS) or NaHS (100 μM; dissolved in 
DMEM, supplemented with 10% (vol/vol) FBS) for 6 h or 24 h. Total RNA was harvested 
using the PeqGold total RNA kit.  The company IMGM Laboratories (Martinsreid, Germany) 
performed the microarray analyses by using an Agilent SurePrint G3 Mouse Gene Expression 
Microarray (8×60K) in combination with a one-color based hybridization protocol. Signals 
were detected using an Agilent DNA Microarray Scanner. Based on the PANTHER analysis, 
the induced and repressed genes were additionally categorized for involvement in molecular 
functions, functional biological processes, cellular components, and protein classes and 
pathways. 
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 Transgenic mice 
 
All animal procedures were approved by the local authority, the Regierungspräsidium 
Darmstadt (approval B2/327). The generation of Cbs-/- mice, where a neomycin selection 
cassette replaced a genomic fragment containing exons 3 and 4 of the Cbs gene, has previously 
been reported (Watanabe et al., 1995). These mice referred to here as Cbs-/-, (strain designation 
B6.129P2-Cbstm1Unc/J), were obtained from The Jackson Laboratory (stock number 002853). 
The generation of Cth-/- mutant mice has already been defined, where exons 1 to 6 were replaced 
with a LacZ and neomycin selection cassette (Ishii et al., 2004) herein referred to as Cth-/-.  
 
 Genotyping of mouse genomic DNA 
 
To genotype transgenic mice semi-quantitative PCR analysis was performed using genomic 
DNA isolated from tail-cuts as template. The DNA extraction from mouse tail cuts was 
achieved according to the Nature protocol ISSN: 1754-2189, EISSN: 1750-2799. The PCR for 
genotyping Cbs-/- mice, was assessed following the protocol described in the Jackson 
Laboratory (category: stock number: 002461, strain name: B6.129P2-Cbstm1Unc/J). The 
polymerase used for the PCR reaction was PfuUltra™ High-Fidelity DNA polymerase (Thermo 
Scientific). The PCR for genotyping Cth-/-, was performed as described previously (Ishii et al., 
2004) using a Hot GoTaq® DNA polymerase (Promega). The primer sequences for genotyping 
are described in Table 3. 
 
 Statistical analyses  
 
Differences between groups were compared by one-way analysis of variance (ANOVA) with 
Tukey’s post hoc test (when more than two groups were compared), or Student’s t test (in the 
case of a comparison of two groups, or pair-wise comparisons of wild-type lungs with either 
Cbs-/- mouse lungs or Cth-/- mouse lungs). Plus, a two-way ANOVA was used for the wound 
healing assay assessed at multiple time-points. Statistical analyses were performed with 
GraphPad Prism 6.0, and statistical outliers were identified by Grubb’s test. A p value <0.05 
was considered significant. 
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11 Results 
 
 Systemic H2S administration partly restores normal 
alveolarization in an experimental animal model of BPD 
 
11.1.1 Stereological analysis of lung structure in normally and aberrantly 
developing lungs 
 
Neonatal mouse pups exposed to 85% O2 for the first 10 days of life presented an evident 
increase in MLI. In normally-developing lungs (21% O2 group) the MLI ranged from 47.2 ± 
1.2 µm whereas in the aberrantly-developing lungs (85% O2 group) the MLI increased to 83.3 
± 4.8 µm without any changes in total lung volume (Fig. 8E; Table 5). An increase of 29% in 
mean septal thickness was also observed in the aberrantly-developing lungs, the mean septal 
thickness ranged from 11.69 ± 0.10 µm compared to 9.05 ± 0.61 µm in normally-developing 
lungs (Fig. 8F). Accordant with the changes in MLI (Fig. 8E), the total number of alveoli 
decreased 56%, from 2.10 ± 0.23 × 106 alveoli/both lungs in normally-developing lungs to 0.92 
± 0.08 × 106 alveoli/both lungs in aberrantly-developing lungs (Fig. 8G).  
 
11.1.2 Stereological analysis of the impact of H2S donor administration on 
normal and aberrant late lung development 
 
Mouse pups maintained at 21% O2 environment and treated with the slow-release H2S donor 
GYY4137 did not have alterations of total number of alveoli per lung, septal thickness or MLI 
(Fig. 8). Still, mouse pups maintained at 85% O2 environment and treated with GYY4137 
resulted in a partial normalization of lung structure. The total number of alveoli per lung was 
almost doubled, increasing from 0.92 ± 0.08 × 106 alveoli/both lungs in vehicle-treated mice to 
1.70 ± 0.15 × 106 alveoli/both lungs in GYY4137-treated mice (Fig. 8F). Accordant with this 
tendency, the MLI was decreased by 21%, from 83.3 ± 4.8 µm in vehicle-treated mice to 65.7 
± 4.3 µm in GYY4137-treated mice (Fig. 8E). Moreover, the mean septal wall thickness also 
was normalized, decreasing by 23%, from 11.69 ± 0.10 µm in vehicle-treated mice to 8.99 ± 
0.34 µm in GYY4137 treated mice (Fig. 8D). Altogether, these data (additional parameters in 
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Table 5) indicate that treatment of an H2S donor to hyperoxia-exposed mice partially normalizes 
lung structure.  
 
 
 
 
Figure 8 GYY4137 administration decreased impaired alveolar development in an experimental mouse 
model of bronchopulmonary dysplasia.  
Illustrative lung tissues sections from mouse pups at postnatal day 10. Mouse pups were exposed either 
to normoxia conditions, 21% O2 (A, C), or to normobaric hyperoxia 85% O2 (B, D) for the first 10 days 
of life. Mouse pups were treated either with a vehicle control (A, B) or with GYY4137 (C, D). Structural 
lung changes were assessed via stereology analysis, including the parameters number of alveoli (E), 
septal thickness (F) and mean linear intercept (G), additional parameters are presented in Table 5. Data 
represent the mean ± S.E. (n=6, per group). The p values were determined by one-way ANOVA with a 
Tukey’s post hoc test (Madurga et al., 2014).  
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Table 5 Structural parameters of developing mouse lungs during exposure to 21% O2 or 85% O2 assessed by stereological analysis (Madurga et 
al., 2014). 
 
 
V, volume; VV, volume density; S, surface area; SV, surface density; CV, coefficient of variation; par, parenchyma; non-par, non-parenchyma; alv air, alveolar 
airspaces; alv epi, alveolar epithelium; sep, septum. Values are presented as mean  S.E, n=6 lungs per group. p values were calculated by one-way ANOVA 
with Tukey’s post-hoc analysis. 
Parameter 21% O2 85% O2 
 H2O  GYY4137  H2O  GYY4137  
mean  S.E. mean  S.E. mean  S.E. p value versus 
H2O/21% O2 
mean  S.E. p value versus 
H2O/85% O2 
V (lung) [cm3] 0.19 ± 0.02 0.22 ± 0.01 0.19 ± 0.01 0.9984 0.20 ±0.01 0.9874 
CV  [V (lung)] 0.25 0.11 0.17 0.13 
VV  (par/lung) [%] 90.9 ± 2.0 95.0 ± 1.3 92.1 ± 2.2 0.9580 91.5 ± 1.0 0.9922 
VV  (non-par/lung) [%] 9.06 ± 1.95 5.05 ± 1.32 7.87 ± 2.21 0.6926 8.53 ± 1.03 0.7804 
SV   (alv epi/par)  [cm-1] 576.4 ± 34.3 598.3 ± 26.1 383.3 ± 18.9 0.0002 480.1 ± 23.5 0.0739 
S (alv epi, lung) [cm2] 96.0 ± 10.9 127.4 ± 8.3 66.1 ± 6.4 0.0530 83.8 ± 6.7 0.4498 
CV [S (alv epi, lung)] 0.28 0.16 0.24 0.20 
V (alv air, lung) [cm3] 0.16 ± 0.01 0.12 ± 0.02 0.14 ± 0.01 0.5332 0.14 ± 0.01 >0.9999 
CV [V (alv air, lung)] 0.22 0.24 0.19 0.12 
V (sep, lung) [cm3] 0.05 ± 0.01 0.08 ± 0.01 0.04 ± 0.01 0.5349 0.04 ± 0.003 0.9933 
CV [V (sep, lung)] 0.13 0.37 0.35 0.21 
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11.1.3 Analysis of H2S donor administration on inflammatory cell infiltration 
in neonatal mouse pup lungs 
 
The anti-inflammatory properties of H2S have been previously described by other groups (Li 
et al., 2011; Wallace et al., 2012). It has also been noted the importance of inflammatory cells 
to normal and aberrant late lung development (Ambalavanan et al., 2009; Deng et al., 2000; 
Hartling et al., 2012; Kunzmann et al., 2013). For that reason, the inflammatory cell infiltration 
into the alveolar airspaces was determined in both 21% O2- and 85% O2-exposed lungs, with 
either vehicle or GYY4137 administration, in cytospins from BAL fluid (Fig. 9). Mouse pups 
exposed to 85 % O2 presented an increase in the abundance of leukocytes in BAL fluid (Fig. 
9B versus Fig. 9A; quantified in Fig. 9E). In detail, the 85% O2-exposed mouse pups had an 
increase in the abundance of macrophages and neutrophils in BAL fluid (Fig. 9G). Plus, the 
hyperoxia exposed mice also had an elevated abundance of monocytes (Fig. 9H), eosinophils 
(Fig. 9I) and lymphocytes (Fig. 9J) in the BAL fluid. Administration of GYY4137 to mouse 
pups exposed to 85% O2 environment changed the BAL fluid inflammatory cell profile (Fig. 
9D versus Fig. 9C; quantified in Fig. 9E). In detail, the infiltration that was provoked by 
exposure to 85% O2 of macrophages (Fig. 9F), neutrophils (Fig. 9G), monocytes (Fig. 9H), and 
eosinophils (Fig. 9I) decreased after GYY4137 treatment, but not lymphocytes (Fig. 9J). 
Therefore, the reduction of inflammatory response by exposure to hyperoxia conditions after 
GYY4137 administration, may represent a mechanism by which GYY4137 was able to 
partially restore normal lung structure to 85 % O2-exposed mouse pups.  
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Figure 9 GYY4137 administration diminished leukocyte recruitment into the alveolar airspaces that 
was provoked by exposure to hyperoxia.  
Representative cytospins images from bronchoalveolar lavage (BAL) fluid from mouse pups at post-
natal day 10. Mouse pups were exposed either to 21% O2 (A, C) or 85% O2 (B, D) for the first 10 days 
of life, and treated either with a vehicle control (water) (A, B) or with GYY4137 (50 mg/kg/day, 
intraperitoneal) (C, D). Arrows indicate neutrophils. E, assessment of the total leukocyte number in 
BAL fluid cytospins; F, number of macrophages present in BAL fluid cytospins; G, number of 
neutrophils present in BAL fluid cytospins; H, number of monocytes present in BAL fluid cytospins; I, 
number of eosinophils present in BAL fluid cytospins; J, number of lymphocytes present in BAL fluid 
cytospins. Data represent the mean ± S.E. (n=6, per group). The p values were determined by one-way 
ANOVA with a Tukey’s post hoc test (Madurga et al., 2014).  
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11.1.4 Cytokine response to GYY4137 administration 
 
Lung homogenates of mouse pups exposed to 21% O2 or 85% O2, with and without 
concomitant GYY4137 administration were evaluated to study the expression levels of the 
cytokines IL-6 (Fig. 10A), IL-10 (Fig. 10B), TNFα (Fig. 10C) and IL-1α (Fig. 10D) by ELISA 
in an effort to comprehend the anti-inflammatory properties of GYY4137 administration. In 
mouse pup lungs exposed to 85% O2 the expression levels of the pro-inflammatory IL-6 were 
increased, and the expression levels of the anti-inflammatory IL-10 were decreased (Fig. 10) 
generating a pro-inflammatory environment. Meanwhile the IL-6 expression levels were not 
impacted in the developing lungs of mouse pups treated with GYY4137 and exposed to 85% 
O2 (Fig: 10A), the IL-10 expression levels were otherwise restored (Fig. 10B). Remarkably, it 
was also noted that mouse pups exposed to 21% O2 environment and treated with GYY4137 
had a reduction of IL-10 expression levels. In sum, GYY4137 may partially restore the pro-
inflammatory environment provoked by hyperoxia conditions that caused an increase of IL-6 
and a decrease of IL-10, restoring pulmonary IL-10 levels that were otherwise depressed in the 
85 % O2 environment (Fig. 10).  
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Figure 10 GYY4137 administration alters the pulmonary expression of inflammatory mediators in 
neonatal mouse lungs.  
Changes in protein expression levels of IL-6 (A), IL-10 (B), tumor necrosis factor alpha (TNFα) (C), 
and IL-1β (D) by ELISA determination in lung tissue homogenates of mouse pups exposed to either 
21% O2 or 85% O2 for the first 10 days of life, that received either vehicle (water) or GYY4137 (50 
mg/kg/day, intraperitoneal). Data represent the mean ± S.E. (n=5-6, per group). The p values were 
determined by one-way ANOVA with a Tukey’s post hoc test (Madurga et al., 2014).  
 
11.1.5 Impact of GYY4137 on the oxidative status of the developing lung 
 
The gasotransmitter H2S has also been reported to have anti-oxidant properties in addition to 
anti-inflammatory properties (Li et al., 2011; Wallace et al., 2012). Hence, the oxidative status 
of the developing lungs was studied, assessed via the ratio of GSH to GSSG in protein extracts 
from mouse pup lung homogenates. Meanwhile mouse pups lungs exposed to hyperoxia 
conditions decreased the GSH/GSSG ratio (Fig. 11), GYY4137 administration did not impact 
the GSH/GSSG ratio (Fig. 11). From this data it is suggestive that the ability of GYY4137 to 
partially restore normal lung structure to 85% O2 exposed mouse pups was not dependent upon 
the anti-oxidative properties of H2S. 
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Figure 11 GYY4137 administration does not impact the oxidative status of neonatal mouse lung as 
assessed by glutathione oxidation.  
Assessment of oxidative status from mouse pup lung homogenates via ratio of reduced glutathione 
(GSH) to oxidized glutathione (GSSG). Mouse pups were exposed either to 21% O2 or 85% O2 for the 
first 10 days of life, and received either vehicle (water) or GYY4137 (50 mg/kg/day, intraperitoneal). 
Data represent the mean ± S.E. (n=6-8, per group). The p values were determined by one-way ANOVA 
with a Tukey’s post hoc test (Madurga et al., 2014).  
 
11.1.6 Impact of NaHS on viability of primary mouse alveolar type II cells 
 
Further studies were focused in the alveolar epithelium, since the epithelium that lines the 
alveolar air spaces would be in direct contact with the increased oxygen levels and therefore 
prone to oxygen-induced injury. Moreover, the epithelium may promote or inhibit 
inflammation in the developing lung since is an important site of generation of inflammatory 
mediators. In addition, if H2S gas would be administered to ventilated patients, the epithelium 
would be likely the first tissue barrier to encounter H2S.  
For the evaluation of how H2S would impact the alveolar epithelium, the H2S donors were 
employed in microarray studies, in cell wounding and cell signaling studies.  
First, the impact of cell viability on ATII cells was assessed using the NaHS donor (100 µM) 
to confirm that the dose used was not toxic to ATII cells over the time-frame of treatment (24 
h) employed. No noticeable apoptosis was detected on ATII cells by flow cytometry based on 
annexin V translocation and propidium iodide permeability (Fig. 12A, quantified in Fig. 12C). 
Likewise, NaHS treatment did not cause appreciable apoptosis to ATII cells, as assessed by 
fluorescence microscopy based on propidium iodide permeability and DAPI nuclear staining 
(Fig. 12B, quantified in Fig. 12D).  
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Figure 12 H2S delivered exogenously by a chemical donor does not cause apoptosis or cell death of 
primary mouse alveolar type II cells.  
The fast release H2S donor NaHS (100 μM, 24 h) was employed for all in vitro studies. As positive 
apoptosis control, cells were treated with staurosporine (1.5 μM, 1.5 h). A, by flow cytometry apoptosis 
was assessed in primary mouse ATII cells to detect annexin V in the outer surface of the cell membrane 
and propidium iodide entry into cells. B, representative images of ATII cells treated either with vehicle 
(DMEM media), NaHS or staurosporine staining with DAPI and propidium iodide (PI) to detect 
apoptosis of cells. C, data were quantified from multiple experiments depicted in (A). D, data were 
quantified from multiple experiments depicted in (B). Data represent the mean ± S.E. (n=4-5, per 
group). The p values were determined by one-way ANOVA with a Tukey’s post hoc test. The scale bar 
indicates 75 µm (Madurga et al., 2014). 
 
11.1.7 Impact of NaHS and GYY4137 treatment on gene expression in primary 
mouse alveolar type II cells 
 
Primary ATII cells were treated either with vehicle (DMEM media) or with H2S donors 
(delivered by NaHS or GYY4137 100 µM for 24 h) both at 21% O2 and 85% O2 conditions, to 
study the changes of gene expression in the alveolar epithelium via microarray analysis (Fig. 
13). Dramatic changes in mRNA expression profiles occurred when primary mouse ATII cells 
were exposed to an 85% O2 environment for 24 h, measured by microarray analysis. The 20 
most up-regulated genes and 20 most down-regulated genes are indicated in Table 6 and Table 
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7, respectively. Yet, GYY4137 and NaHS administration did not have any effect on gene 
expression in primary mouse ATII cells. From this data, it is suggestive that the partially restore 
of lung structure to oxygen-injured developing mouse lungs treated with H2S donors was not 
dependent on changes in gene expression in alveolar epithelial cells 
 
 
 
Figure 13 Scheme representing the experimental settings of primary alveolar type II cells exposed to 
hydrogen sulfide donors.  
Scheme of experimental settings of primary alveolar type II (ATII) cells treated either with vehicle or  
NaHS 100 µM for 6 or 24 h (left side panel) or ATII cells treated either in normoxia or hyperoxia 
conditions, treated either with vehicle (DMEM media) or with GYY4137 100 µM for 24 h (right side 
panel). Both schemes are accompanied by a table showing the gene regulation caused by the treatment 
administration and analyzed by microarray analysis. FC=Fold change (Madurga et al., 2014).  
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Table 6 Gene expression in primary mouse alveolar type II cells up-regulated by exposure to 
85% O2 in vitro.  
 
Gene 
symbol 
(NCBI) 
Fold 
change Gene name 
Svop 8.67 SV2 related protein 
H2-M9 8.54 histocompatibility 2, M region locus 9 
Prl2c5 7.53 prolactin family 2, subfamily c, member 5 
Robo3 6.65 roundabout homolog 3 (Drosophila) 
Zfp750 5.84 zinc finger protein 750 
Tmem45b 5.62 transmembrane protein 45b 
Krtap3-2 5.46 keratin associated protein 3-2 
Apol7d 5.29 apolipoprotein L 7d 
Rprm 5.18 reprimo, TP53 dependent G2 arrest mediator candidate 
Dusp15 5.12 dual specificity phosphatase-like 15 
Nkx2-9 4.98 NK2 transcription factor related, locus 9 (Drosophila) 
Kcnj4 4.86 potassium inwardly-rectifying channel, subfamily J, member 4 
Nr1d1 4.78 nuclear receptor subfamily 1, group D, member 1 
Lrdd 4.70 leucine-rich and death domain containing 
Dcxr 4.55 dicarbonyl L-xylulose reductase 
Cdkn1a 4.28 cyclin-dependent kinase inhibitor 1A (P21) 
Lrdd 4.24 leucine-rich and death domain containing 
Olfr1020 4.15 olfactory receptor 1020 
Dcxr 4.14 dicarbonyl L-xylulose reductase 
Crct1 4.01 cysteine-rich C-terminal 1 
NCBI, national center for Biotechnology Information. 
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Table 7 Gene expression in primary mouse alveolar type II cells down-regulated by exposure 
to 85% O2 in vitro. 
 
Gene 
symbol 
(NCBI) 
Fold 
change Gene name 
Hist1h1b -15.89 histone cluster 1, H1b 
Hist2h2bb -11.84 histone cluster 2, H2bb 
Cep55 -9.94 centrosomal protein 55 
Cdc6 -8.78 cell division cycle 6 homolog (S. cerevisiae) 
Mki67 -8.35 antigen identified by monoclonal antibody Ki 67 
Casc5 -8.18 cancer susceptibility candidate 5 
Kif11 -8.14 kinesin family member 11 
Mxd3 -8.13 Max dimerization protein 3 
Aspm -8.10 
asp (abnormal spindle)-like, microcephaly associated 
(Drosophila) 
Ndc80 -7.88 
NDC80 homolog, kinetochore complex component (S. 
cerevisiae) 
Mki67 -7.84 antigen identified by monoclonal antibody Ki 67 
Sgol2 -7.80 shugoshin-like 2 (S. pombe) 
Hist1h1a -7.74 histone cluster 1, H1a 
Plk1 -7.15 polo-like kinase 1 (Drosophila) 
Fbxo5 -7.08 F-box protein 5 
Kif2c -6.98 kinesin family member 2C 
Kif2c -6.51 kinesin family member 2C 
Nuf2 -6.51 
NUF2, NDC80 kinetochore complex component,  
homolog (S. cerevisiae) 
Depdc1b -6.17 DEP domain containing 1B 
E2f8 -6.14 E2F transcription factor 8 
NCBI, national center for Biotechnology Information. 
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11.1.8 Impact of NaHS on primary mouse alveolar type II cell wound closure 
 
Taken into account that H2S administration (delivered by NaHS and GYY4137) did not impact 
gene expression in primary ATII cells, it was likely that H2S could influence other processes 
during lung development and repair that implied ATII cells. Thus, using the fast release H2S 
donor NaHS, a classical wound repair assay was performed on primary ATII cell monolayers. 
The NaHS promoted wound repair assessed by the rate of wound closure (Fig. 14B versus     
Fig. 14D, quantified in Fig. 14I and Fig. 14J). Though glibenclamide, a sulfonylurea that 
inhibits ATP-sensitive potassium channels and the cystic fibrosis transmembrane conductance 
regulator, was with no effect on ATII cell wound closure, glibenclamide (Fig. 14F versus      
Fig. 14B; quantified in Fig. 14I and Fig. 14J) did blunt the ability of NaHS to promote would 
closure (Fig. 14H versus Fig. 14D; quantified in Fig. 14I and Fig. 14J). Taken together this 
data suggest that H2S (released from NaHS) can promote wound healing in ATII cells, and that 
this process depends on the interaction of H2S with glibenclamide, implying involvement of 
ion channels in ATII cells. Moreover, this data suggest a hint in the mechanism of action of 
H2S to restore proper lung development in oxygen-injured lungs.
 
Figure 14 NaHS promotes wound closure in monolayers of primary mouse alveolar type II cells.  
Illustrative images taken at 0 h and 24 h representing wound closure in primary mouse alveolar type II 
(ATII) cell monolayers, in vehicle-treated (A, B), NaHS-treated (C, D), glibenclamide-treated (E, F), 
NaHS and glibenclamide-treated (G, H) ATII cells. I, data quantification for multiple experiments 
assessing wound closure at 24 h. Data represent the mean ± S.E. (n=6, per group). The p values were 
determined at one-way ANOVA with a Tukey’s post hoc test. J, wound closure dynamics in primary 
mouse ATII cell monolayers over 24 h. Data represent the mean ± S.E. (n=6, per group). The p values 
were determined by two-way ANOVA (Madurga et al., 2014). 
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11.1.9 Impact of NaHS on Akt signaling in primary mouse alveolar type II cells 
 
Further studies focused in the effect of NaHS treatment on protein kinase B (Akt) (Fig. 15), 
since Akt is known to play a role in repair processes in epithelial cells and to protect against 
hyperoxia-induced damage to the lung (Alphonse et al., 2011).  
Measuring Akt phosphorylation as activation of the Akt pathway, NaHS (100 µM) treatment 
into ATII cells (Fig. 15A) and the MLE-12 mouse lung epithelial cell line (Fig. 15B) resulted 
in a fast (with 30 min) activation of the Akt pathway. Thus, H2S delivery through NaHS may 
have a cell wound healing effect on ATII cells through activation of the Akt pathway. 
Moreover, the effect of H2S administration (through GYY4137 treatment) on the activation of 
the Akt pathway was also assessed in vivo, in mouse pup lungs exposed either to 21% O2 or 
85% O2 environment conditions (Fig. 15C). Hyperoxia conditions reduced the total levels of 
Akt protein, nonetheless GYY4137 administration although also had reduced levels of total 
Akt, promoted activation of Akt pathway (as assessed by phosphorylation) in the developing 
lung. Therefore, these data encourages the idea that Akt activation by GYY4137 might underlie 
some of the lung-protective effects in oxygen-injured lungs from mouse pups.  
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Figure 15 H2S donors promote activation of Akt.   
A, immunoblot representing protein expression levels of total Akt (tAkt) and levels of phosphorylated 
Akt (pAkt) from primary mouse alveolar type II (ATII) treated with NaHS, for 10, 15, 20, 30 or 60 min 
in cell protein extracts (25 µg). Data quantification of activated Akt was measured the ratio of 
phosphorylated to total Akt. B, similar data were obtained using MLE-12 cells. C, immunoblot 
representing protein expression levels of total (tAkt) and levels of phosphorylated Akt (pAkt) of protein 
extracts (20 µg) from mouse pup lungs exposed to either 21% O2 or 85% O2 for the first 10 days of life, 
that received either H2O or GYY4137 (50 mg/kg/day, intraperitoneal). Data represent the mean ± S.D. 
(n=3, per group). The p values were determined by one-way ANOVA with a Tukey’s post hoc test 
(Madurga et al., 2014).   
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 The role of Cbs and Cth during late lung development 
 
11.2.1 The expression of Cbs and Cth is dynamically regulated during 
alveolarization 
 
Cbs and Cth are both enzymes that generate and regulate the release of H2S in human and 
mouse (Nagahara, 2011; Olson, 2011; Wang, 2003, 2010). The expression mRNA levels of 
Cbs and Cth was dynamically regulated over the course of late lung development (Figure 16). 
Regarding Cbs, the data illustrates that the expression of Cbs was 16-fold down regulated 
between P2.5 and P3.5 over a period of 24 h, an remained down-regulated on P5.5 concomitant 
with the peak of septation at P5.5 (Massaro & Massaro, 2007; Warburton et al., 2010; 
Warburton et al., 2000). At P9.5, after secondary septation was mostly completed, the 
expression of Cbs was up-regulated 32-fold. Regarding Cth, the data illustrates that the 
expression of Cth was regulated in an opposite manner in comparison to Cbs. The expression 
of mRNA encoding Cth was four-fold up-regulated between P2.5 and P3.5, over a period of 
24 h, and the peak of up-regulation was highest on P5.5, after which decreased by eight-fold 
on P9.5. This changing regulation of Cbs and Cth in an inverse manner with one another, points 
a role for Cbs and Cth during post-natal lung development. 
 
  
 
Figure 16 RT-PCR to assess changes of mRNA expression of Cbs and Cth, on different time points 
during normal late lung development.  
Data represent the mean ΔCt ± S.E. (n=4, per group). The ΔCt values were compared by one-way 
ANOVA and Tukey’s post hoc test. The primers used for the RT-PCR are listed in Table 2. 
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11.2.2 The expression of both Cbs and Cth can be abrogated during post-natal 
lung development in mice 
 
To genotype transgenic mice semi-quantitative PCR analysis was performed using genomic 
DNA isolated from tail-cuts as template (primers listed in Table 3). Regarding Cbs, pups were 
generated from heterozygous parental animals, a single 450-bp band identified Cbs-/- 
homozygotes, a single 300-bp band identified wild type mice, or a 300-bp band together with 
a 450-bp band identified heterozygous mice (Fig. 17A). Immunoblot was used to confirm loss 
of Cbs protein expression (Fig. 18A). Regarding Cth, the homozygous Cth-/- pups were 
obtained by mating homozygous Cth-/- parental animals, a single 199-bp band identified Cth-/- 
pups, while a single 299-bp band identified wild-type animals (Fig. 17B). Immunoblot was 
used to confirm loss of CTH protein expression (Fig. 18B).  
 
 
Figure 17 Genotyping of mouse pups for Cbs and Cth.  
A, illustration of PCR genotyping wild type mice (wt; 300 bp), Cbs heterozygote mice (+/-; 300-bp and 
450-bp) and Cbs-/- mice (-/-; 450-bp). B, illustration of PCR genotyping of wild type mice (wt; 299-bp) 
and Cth-/- mice (-/-; 199-bp). M, marker; wt, wild type. 
 
 
Figure 18 Loss of Cbs and Cth expression in lungs of Cbs-/- and Cth-/- mice by immunoblot.  
A, immunoblot from whole-lung homogenates resolved with an anti-Cbs antibody (67 kDa) in wild-
type mice and Cbs-null homozygotes (-/-). B, same situation as (A) but probed with an anti-Cth antibody 
(50 kDa) in wild type mice and Cth-null homozygotes (-/-). -actin was used as loading control; wt, 
wild type.  
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11.2.3 Loss of Cbs or Cth impairs normal lung alveolarization in mice. Lung 
histology 
 
When inspecting lung histology sections from wild-type mice at P7.5 (Fig. 19A) in comparison 
to age-matched Cbs-/- mice (Fig. 19B) and Cth-/- mice (Fig. 19C), the lung structure of Cbs-/- 
and Cth-/- mice suggested to be less complex - implying fewer but larger alveoli - indicating 
that both Cbs and Cth were necessary for proper late lung development. On P14.5, this effect 
was more evident, and both Cbs-/-mice (Fig. 19E) and Cth-/- mice (Fig. 19F) presented a more 
immature lung structure, with less alveoli and enlarged air spaces compared to wild type mice 
(Fig. 19D).  
 
 
 
Figure 19 Representative lung histology of postnatal day P7.5 and P14.5 of wild type mice, Cbs-/- mice, 
and Cth-/- mice.  
Lung histology representative images at postnatal day P7.5 of wild type mice (A), Cbs-/- mice (B) and 
Cth-/- mice (C). Lung histology representative images of postnatal day P14.5 of wild type mice (D), 
Cbs-/- mice (E) and Cth-/- mice (F). Sections stained with Richardson’s staining at 10 × magnification, 
scale bar of 100 µm. 
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11.2.4 Loss of Cbs or Cth impairs normal alveolarization in mice. Stereology 
analysis 
 
The histological observations were confirmed by stereological analysis which were fully 
evident on P14.5 (Table 8, 9 and Figures 20 and 21). Lung volumes of both Cbs-/- and Cth-/- 
mice decreased approx. 25 % compared to wild type mice. The lung volumes values decreased 
from 0.31 ± 0.01 cm3 in the wild type mice, to 0.23 ± 0.009 cm3 in the Cbs-/- mice and to 0.24 
± 0.02 cm3 in the Cth-/- mice. The number of alveoli of both Cbs-/- and Cth-/- mice lowered down 
to approx. 50% compared to the wild type mice. The number of alveoli decreased from 4.74 ± 
0.42 × 106 alveoli/both lungs in the wild type mice, to 2.30 ± 0.20× 106 alveoli/both lungs in 
the Cbs-/- mice, and to 2.81 ± 0.78 × 106 alveoli/both lungs in the Cth-/- mice. Regarding the 
mean linear intercept, it changed, increasing from 30.85 ± 1.0 µm in wild type mice to 38.15 ± 
3.4 µm in the Cbs-/- mice, and it also increased to 43.2 ± 6.8 µm in the Cth-/- mice.  In regards 
of septal thickness, the values were similar among all the groups, from 10.4 ± 0.4 µm in the 
wild type mice to 12.9 ± 1.8 µm in the Cbs-/- mice and of 9.4 ± 0.6 µm in the Cth-/- mice. 
Moreover, the surface area for gas exchange was smaller in both Cbs-/- and Cth-/- mice when 
compared to the wild type mice. The surface area values decreased almost 50 %, ranging from 
220.8 ± 13.1 cm2 in the wild type mice, to 134.2 ± 5.9 cm2 in the Cbs-/- mice and to 154 ± 22.6 
cm2 in the Cth-/- mice. Taken together, this data suggest that both Cbs and Cth play a role during 
normal late lung development.  
 
 
 
Figure 20 Aberrant late lung development in the Cbs-/- mice and Cth-/- mice assessed via stereology 
methods.  
Stereology analysis on postnatal day P14.5 of wild type mice (wt), Cbs-/- mice and Cth-/- mice 
representing number of alveoli (A), surface area (B) and septal thickness (C). Data represent the mean 
± S.E. (n=5 per group). The differences between groups were determined by unpaired Student t test.  
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Table 8 Stereological parameters of wild type mice, Cbs-/- mice and Cth-/- mice on postnatal day P7.5. 
 
Parameter P7.5 
 Wt Cbs-/- p values 
Wt to Cbs-/- 
Cth-/- p values 
Wt to Cth-/- 
V (lung) [cm3] 0.20 ± 0.02 0.17 ± 0.03 0.448 0.17 ± 0.02 0.2649 
CV  [V (lung)] 0.24 0.36  0.22  
VV  (par/lung) [%] 89.24 ± 2.09 91.01 ± 1.46 0.5076 89.00 ± 1.81 0.9336 
VV  (non-par/lung) [%] 10.76 ± 2.01 8 ± 1.46 0.5076 11.00 ± 1.81 0.9336 
SV   (alv epi/par)  [cm-1] 599.1 ± 34.18 589.7 ± 30.86 0.8423 628.5 ± 22.87 0.4955 
S (alv epi, lung) [cm2] 106.2 ± 14.62 89.42 ± 13.01 0.4149 92.64 ± 10.21 0.4672 
CV [S (alv epi, lung)] 0.31 0.32  0.25  
V (alv air, lung) [cm3] 0.09 ± 0.01 0.08 ± 0.01 0.3997 0.09 ± 0.01 0.9150 
CV [V (alv air, lung)] 0.24 0.24  0.23  
V (sep, lung) [cm3] 0.09 ± 0.01 0.08 ± 0.01 0.5030 0.06 ± 0.007 0.0440 
CV [V (sep, lung)] 0.32 0.49  0.29  
 
Wt, wild type mice; V, volume; VV, volume density; S, surface area; SV, surface density; CV, coefficient of variation; par, parenchyma; non-par, non-parenchyma; 
alv air, alveolar airspaces; alv epi, alveolar epithelium; sep, septum. Values are presented as mean   S.E, n=5 lungs per group. p values were calculated by 
Student t test.  
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Table 9 Stereological parameters of wild type mice, Cbs-/- mice and Cth-/- mice on postnatal day P14.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wt, wild type mice; V, volume; VV, volume density; S, surface area; SV, surface density; CV, coefficient of variation; par, parenchyma; non-par, non-parenchyma; 
alv air, alveolar airspaces; alv epi, alveolar epithelium; sep, septum. Values are presented as mean   S.E, n=5 lungs per group. p values were calculated by 
Student t test.  
Parameter  P14.5  
 Wt Cbs-/- p values 
Wt to Cbs-/- 
Cth-/- p values 
Wt to Cth-/- 
V (lung) [cm3] 0.31 ± 0.01 0.23 ± 0.009 0.0023 0.24 ± 0.02 0.0471 
CV  [V (lung)] 0.12 0.09  0.22  
VV  (par/lung) [%] 93.01 ± 2.2 91.72 ± 2.0 0.6727 92.33 ± 1.8 0.8151 
VV  (non-par/lung) [%] 6.99 ± 2.2 8.28 ± 2.0 0.6728 7.68 ± 1.8 0.8151 
SV   (alv epi/par)  [cm-1] 756.5 ± 15.9 641.2 ± 41.5 0.0320 676.9 ± 65.9 0.2741 
S (alv epi, lung) [cm2] 220.8 ± 13.1 134.2 ± 5.9 0.0003 154 ± 22.6 0.0337 
CV [S (alv epi, lung)] 0.13 0.10  0.33  
V (alv air, lung) [cm3] 0.17 ± 0.01 0.13 ± 0.01 0.0281 0.15 ± 0.02 0.4956 
CV [V (alv air, lung)] 0.16 0.19  0.27  
V (sep, lung) [cm3] 0.12 ± 0.01 0.09 ± 0.01 0.0259 0.07 ± 0.01 0.0045 
CV [V (sep, lung)] 0.18 0.24  0.28  
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11.2.5 Loss of Cbs or Cth affects lung development, transition from P7.5 to 
P14.5 
 
During the transition between P7.5 and P14.5, the changes in lung structure for wild type mice 
(illustrated in blue color), Cbs-/- mice (illustrated in grey color) and Cth-/- mice (illustrated in 
black color) are resumed in figure 21. Interestingly, the rate of lung volume (Fig. 21A), alveoli 
number (Fig. 21C) and surface area (Fig. 21E) augmented more exponentially in the case of 
wild type mice in comparison to both Cbs-/- and Cth-/- mice. These changes were more obvious 
in the case of the Cbs-/- mice. For instance, the number of alveoli per cm3 (Fig. 21B) between 
P7.5 and P14.5 was equivalent between wild type mice and Cth-/- mice whereas was reduced 
in Cbs-/- mice. This situation was also observed in other parameters, like the alveolar septal 
volume (Table 9), suggesting fewer alveoli per unit volume being produced in the Cbs-/- mice. 
Taken together, this data indicates an alveolar impairment during late lung development in  
Cbs-/- and Cth-/- mice, highlighting roles for Cbs and Cth in normal lung growth and maturation. 
 
 
 
Figure 21 Aberrant late lung development in the Cbs-/- mice and Cth-/- mice assessed via stereology 
methods, evolution from P7.5 to P14.5.  
Stereology representation of lung volume (A), number of alveoli per cm3 (B), number of alveoli (C), 
surface density (D), surface area (E) and septal thickness (F). Wild type mice are represented in blue 
color, Cbs-/- mice represented in grey color, and Cth-/- mice represented in black color. Data represent 
the mean ± S.E. (n=5 per group). The p values show the statistics on P14.5 and, the differences between 
groups were determined by unpaired Student t test.   
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11.2.6 Both Cbs and Cth are preferentially expressed in specific lung 
compartments 
 
To identify if Cbs and Cth expression was confined to specific lung compartments, 
cryopreserved sections from mouse pup lungs at P7.5 and P14.5 were micro dissected using a 
laser-capture micro dissection system (Leica LMD 6500). A RT-PCR analysis was used to 
screen the expression of mRNA encoding Cbs and Cth in micro dissected tissue. These two 
time points during late lung development were chosen, the first on P7.5 close to the peak of 
septation, and the other on P14.5 close to the micro vessel maturation (Massaro & Massaro, 
2007; Warburton et al., 2010; Warburton et al., 2000). As is illustrated in figure 22, Cbs was 
more expressed in the airway at P7.5 (Fig. 22A), and in the vascular compartment at P14.5 
compared with the parenchymal compartment (Fig. 22B). In the case of Cth expression, at P7.5 
Cth expression was equivalent in all three compartments (Fig. 22C), but more elevated in the 
airway compartment at P14.5 (Fig. 22D). A representation of the laser-capture micro dissection 
process is presented for the vascular compartment (in this case, most likely a pulmonary artery), 
as an example, in Fig. 22E, 22F, and 22G. 
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Figure 22 Cbs and Cth are mostly expressed in the airway and vascular compartment.  
RT-PCR analysis of Cbs (A) and Cth (C) on P7.5, and of Cbs (B) and Cth (D) on P14.5 to assess the 
expression in the vascular, airway and parenchymal compartment. Data represent the ΔCt ± S.E. (n=4 
per group). The differences between groups were determined by one-way ANOVA with Tukey’s post 
hoc test. The laser-capture micro dissection process is offered for the vessel compartment (in this case 
most likely a pulmonary artery), as an example in E, F and G. Parenchyma compartment (p), airway 
compartment (aw) and vascular compartment (v). Scale bar of 100 µm.   
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11.2.7 Both Cbs and Cth localize to the airways and vessel walls in the lungs 
of mouse pups 
 
Serial sections of wild-type mouse pup lungs were stained by immunofluorescence to detect 
the expression of CBS and CTH in the lung architecture. Serial sections were stained with vWF 
(Fig. 23B) and SMA staining (Fig. 23B) to discriminate the vascular and airway 
compartments. The immunoreactivity for CBS was detected in the airway epithelium and the 
lung vessel walls (Fig. 23A and Fig. 23C). The better immunoreactivity of anti-Cbs antibodies 
in Fig. 23A compared with Fig. 23C is due to the superior performance of anti-Cbs antibodies 
in the vWF staining protocol (Fig. 23A, B) compared with the SMA staining protocol (Fig. 
23C, D). In the same manner as CBS, CTH immunoreactivity was positive in the lung vessel 
walls and the airway epithelium (Fig. 24A and Fig. 24C, respectively). Both CBS and CTH 
were weakly detected in the lung parenchyma (Fig. 23 and Fig. 24, respectively). As negative 
controls, a pre-immune isotype-matched primary antibody (Fig. 23E and Fig. 24E) or lung 
sections from Cbs-/- and Cth-/- mice (Fig. 23F and Fig. 24F, respectively) were 
immunofluorescence stained for both CBS and CTH. The data presented here, validates the 
previously presented data on laser-capture micro dissection gene expression for Cbs (Fig. 22A, 
B) and Cth (Fig. 22C, D), and highlight plausible roles for Cbs and Cth in the in the airways 
and pulmonary vasculature during late lung development. 
 
 
 82 
 
 
Figure 23 Localization of CBS in the airways, vessel walls and alveolar epithelium.  
Serial sections (A combined with B; and C combined with D) were co-stained, to determine CBS 
localization in a mouse lung on P14.5. Serial sections stained for CBS and von Willebrand Factor 
(vWF), to assess Cbs expression in the lung vasculature (A, B); serial sections stained for CBS and 
alpha smooth muscle actin (SMA) to assess expression in the pulmonary smooth muscle (C, D). As 
controls, lung sections were stained using a non-immune IgG as primary antibody instead of the anti-
Cbs antibody (E), and staining for CBS on Cbs-/- mouse lung tissue (F). Cell nuclei were revealed with 
4,6-diamidino-2-phenylindole (DAPI). Scale bar of 25 µm. 
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Figure 24 Localization of CTH in the airways, vessel walls and alveolar epithelium.  
Serial sections (A combined with B; and C combined with D) were co-stained, to determine CTH 
localization in a mouse lung on P14.5. Serial sections stained for CTH and von Willebrand Factor 
(vWF), to assess CTH expression in the lung vasculature (A, B); serial sections stained for CTH and 
alpha smooth muscle actin (SMA) to assess expression in the pulmonary smooth muscle (C, D). As 
controls, lung sections were also stained using a non-immune IgG as primary antibody instead of the 
anti-Cth antibody (E), and staining for CTH on Cth-/- mouse lung tissue (F). Cell nuclei were revealed 
with 4,6-diamidino-2-phenylindole (DAPI). Scale bar of 25 µm. 
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11.2.8 Both Cbs and Cth contribute to the development or maintenance of 
normal pulmonary vasculature 
 
Blood vessels in the lung play an important role promoting normal lung development and 
preserving correct alveolar structures throughout alveologenesis. An incorrect or poor blood 
flow distribution may outcome in lung abnormality (Iosef et al., 2012; Pereda et al., 2013; 
Thebaud, 2007).  
Taking into account that both Cbs-/- mice and Cth-/- mice have an impaired lung development, 
and that both CBS and CTH are mainly expressed in the vessel and airway compartment, 
attention was driven to the density of vessels for both Cbs-/- and Cth-/- mice. 
Using antibodies against αSMA, vWF, and performing a Van Gieson staining with Fuchsin-
Resorcin in paraffin embedded neonatal lung mouse sections, the vessel density, the vessel 
muscularization and the MWT index of vessels was counted. As it is illustrated in Figure 25, 
an approximation of vascular supply by visual inspection of histological sections from 
developing mouse lungs was diminished (Fig. 25) in both Cbs-/- mice (Fig. 25C) and Cth-/- mice 
(Fig. 25D) compared to wild type mice (Fig. 25B). Furthermore, lung homogenates from 
postnatal wild type mice, Cbs-/- mice and Cth-/- mice were evaluated for measuring the 
expression of CD31 [platelet endothelial cell adhesion molecule (PECAM)-1], an endothelial 
marker. Remarkably, the expression of CD31 was lower in lung homogenates from both       
Cbs-/- and Cth-/- mice when compared to wild type mice as it is shown in Figure 25 (Fig 25 E 
and F) suggesting that the loss of Cbs or Cth may result in deficient vascular growth in 
developing mouse lungs.   
The degree of muscularization of pulmonary vessels (Fig. 26) indicated that the genetic absence 
of Cbs (Fig. 26E) and Cth (Fig. 26F) led to a pronounce increase in the degree of 
muscularization of small vessels (diameter 20-70 µm). Additionally, increased muscularization 
of medium vessels (diameter 70-150 µm) was also noted in the Cbs-/- mice. The degree of 
muscularization had no affection on the large vessels (diameter >150 µm). Consistent with this 
experiment, the measurement of the MWT index showed the same trend as the degree of 
muscularization for both Cbs-/- and Cth-/- mice (Figure 27). Taken together, this data suggests 
that both Cbs and Cth play a role in the development or maintenance of the normal pulmonary 
vasculature in developing mouse lungs. 
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Figure 25 Decreased vascular supply in the Cbs-/- mice and the Cth-/- mice.  
A, quantification of vascular supply per field and per group: Wild type mice (wt), Cbs-/- mice and Cth-/- 
mice. Representative stained sections are illustrated for wild type mice (B), Cbs-/- mice (C) and Cth-/- 
mice (D), stained with von Willebrand factor (brown) and alpha smooth muscle actin (purple). 
Magnification 20×, scale bar of 100 µm.  Data represent the mean number of vessels cross-section per 
microscopic field ± S.E. (n=3-4, per group). The p values were determined by one-way ANOVA with 
Tukey’s post hoc test. E and F, total mouse pup lung homogenates were tested for CD31 expression by 
immunoblot. The histogram represents the mean ± S.E. normalized pixel density were the CD31 band 
was normalized for the pixel density of the β-actin band from the same sample (n=3, per group). 
Differences between groups were determined by one-way ANOVA with Tukey’s post hoc test.  
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Figure 26 Loss of Cbs or Cth promotes increased muscularization of small pulmonary vessels. The 
degree of muscularization of lung vessels were calculated in three different groups: Small vessels 
(diameter 20-70 µm) (A), medium vessels (diameter 70-150 µm) (B) and large vessels (diameter >150 
µm) (C). Illustrative stained sections are represented for wild type (D), Cbs-/- mice (E) and Cth-/- mice 
(F). Staining of alpha smooth muscle actin (purple) and von Willebrand factor (brown), 40× 
magnification, scale bar of 50 µm. Data represent the mean muscularization (%) ± S.E. (n=3-4, per 
group). Differences between groups were determined by one-way ANOVA with Tukey’s post hoc test. 
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Figure 27 Loss of Cbs or Cth leads to an increase in an index of medial wall thickness in small 
pulmonary vessels.The index of medial wall thickness (MWT) was determined in van Gieson-stained 
paraffin embedded lung sections from wild-type mice, Cbs-/- mice and Cth-/- mice, and differentiated in 
three different groups: Small vessels (diameter 20-70 µm) (A), medium vessels (diameter 70-150 µm) 
(B) and large vessels (diameter >150 µm). Illustrative stained sections are represented for wild type 
mice (D), Cbs-/- mice (E) and Cth-/- mice (F), 40× magnification, and scale bar of 50 µm. Data represent 
the mean muscularization (%) ± S.E. (n=3-4, per group). Differences between groups were determined 
by one-way ANOVA with Tukey’s post hoc test. 
 
  
 88 
11.2.9 Both Cbs and Cth participate in the angiogenesis of human pulmonary 
microvascular endothelial cells 
 
To further comprehend the role of CBS in the angiogenesis of HPAEC, a Matrigel assay was 
performed after transfecting HPAEC cells either with scrambled (200 nM) or siRNA CBS (200 
nM) for 48 h, and loaded into the Matrigel for 24 h, represented in Figure 28. Inhibition of CBS 
expression did not affect the number of tubes formed (Fig. 28D), yet strongly disturbed tube 
length (Fig. 28C). An immunoblot is represented (Fig. 28E) assessing the efficiency of the CBS 
knockdown, and quantified in Fig. 28F. The HPAEC were also tested to study the role of CTH 
in angiogenesis (Fig. 29). Several attempts to use siRNA to inhibit CTH were unsuccessful 
(results not shown). Still, propargylglycine (PAG) is a small-molecule known to ablate the 
expression of CTH (Papapetropoulos et al., 2009; Szabó, 2011), and at both 1 mM and 3 mM 
concentration, PAG effectively reduced the formation of vessels and the length of vessels (Fig. 
29C and D). Furthermore, GYY4137, a H2S donor, increased meaningfully the formation of 
new tubes when compared to vehicle, and also increased the length of vessels (Fig. 29B). In no 
case did siRNA, GYY4137 or PAG treatments any consequence on HPAEC viability (results 
not shown). These data support the idea that both Cbs and Cth play a role in the formation of 
endothelial tubes formed, since their inhibition interrupts a proper vessel network formation, 
and that hydrogen sulfide, a byproduct of their reaction, promotes it. 
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Figure 28 Inhibition of CBS expression alters tube formation in vitro.  
Tube formation assay of human pulmonary endothelial cells in a Matrigel plate using either scrambled 
or siRNA CBS. Representative pictures were taken from scrambled 200 nM (A) and siRNA CBS 200 
nM (B) after 48 h of transfection and 24 h incubation in a Matrigel plate. Magnification 5×, scale bar 
50 µm.  Quantification of number of tubes (C) and quantification of tube length (D), protein expression 
levels of CBS (25 µg) showing the efficiency of CBS knockdown by siRNA treatment was assessed by 
immunoblot of cell homogenates and probed with anti-CBS antibody (E). The bands from (E) were 
quantified by densitometry analysis (F). Data represent the mean ± S.E. (n=3, per group). Differences 
between groups were determined by unpaired Student t test. 
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Figure 29 CTH and H2S modulate endothelial tube formation in vitro.  
Tube formation assay of human pulmonary endothelial cells in a Matrigel plate after pre-treatment using 
either vehicle alone, propargylglycine (PAG) or GYY4137. Representative pictures were taken from 
vehicle alone (A), GYY4137 100 µM (B), PAG 1 mM (C) and PAG 3 mM (D). Magnification 5×, scale 
bar 50 µm.  Quantification of tube length (E) and number of tubes (F), Data represent the mean ± S.E. 
(n=3, per group). Differences between groups were evaluated by one-way ANOVA with Tukey’s post 
hoc test.   
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12 Discussion 
 
The first central question of this study was: Does systemic administration of H2S (via the slow-
release H2S donor GYY4137) improve alveolarization of immature lungs that are exposed to 
85% O2 environment over the perinatal period? The starting approach of the study was to 
perform a stereological analysis to assess changes in the lung structure of developing lungs that 
were damaged by hyperoxia exposure. The experiment involves the prior maintenance of the 
lung structure, continued with SUR sampling and followed by the stereological analysis for the 
determination of the total number of alveoli, MLI and septal thickness (Schneider & Ochs, 
2013). Nowadays this approach represents the highest standard in lung structural analysis 
available, recommended by both the European Respiratory Society and the American Thoracic 
Society (Hsia et al., 2010). The Green Journal has evaluated the pros and cons of this approach 
in a recent review (Muhlfeld & Ochs, 2013; Ochs & Muhlfeld, 2013). Up until now, other 
groups have assessed the stereological analysis of adult lungs (Fehrenbach et al., 2008; 
Knudsen et al., 2013; Knust et al., 2009; Muhlfeld & Ochs, 2013; Ochs & Muhlfeld, 2013; 
Schneider & Ochs, 2013, 2014). Still, this study presents for the first time the changes in the 
lung structure of immature mouse pup lungs during perinatal development (Madurga et al., 
2014). From the stereological analysis, it was observed a dramatic reduction in the total number 
of alveoli in the lung, from 2.10 ± 0.23 × 106 alveoli/both lungs in mice exposed to 21% O2 for 
the first ten days of life to 0.92 ± 0.08 × 106 alveoli/both lungs in mice exposed to 85% O2 for 
the first ten days of life. Moreover, the septal thickness was also affected, by a 29% increase. 
Administering GYY4137, a slow-release H2S donor, partially restored the lung abnormalities 
caused by the effects of hyperoxia on mouse late lung development. Administration of 
GYY4137 doubled the total number of alveoli in GYY4137-treated mouse pups, from 0.92 ± 
0.08 × 106 alveoli/both lungs in vehicle-treated pups exposed to 85% O2, to 1.70 ± 0.15 × 10
6 
alveoli/both lungs in GYY4137-treated pups exposed to 85% O2, and normalized septal 
thickness. Nonetheless, the significant improvement in the number of alveoli caused by the 
GYY4137 administration, still fell short in comparison to the 2.10 ± 0.23 × 106 alveoli/both 
lungs present in the healthy control group of mouse pups at P10 that breathed 21% O2. The 
above mentioned data confirms that H2S administration can partially reduce the impaired 
alveolarization of immature mouse lungs caused by exposure to 85% O2 over the perinatal 
period (Madurga et al., 2014). 
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The protective effects of H2S on disrupted late lung development provoked by 
hyperoxia, may have been caused by the accredited physiological characteristics of H2S. These 
properties include antioxidant, anti-inflammatory, vasoactive and cytoprotective activities 
ascribed to H2S (Stein & Bailey, 2013). On the other hand, impaired alveolarization in response 
to hyperoxia is related to inflammation (Blackwell et al., 2011), oxidative stress (Saugstad, 
2010), cell death and apoptosis (Dieperink et al., 2006), and perturbed pulmonary vascular 
development and hemodynamics (Thebaud & Abman, 2007; Thebaud et al., 2005). In that 
context, it was demonstrated in this study the anti-inflammatory properties of H2S in repairing 
lung development to mouse pups. Hyperoxia induced inflammatory cell infiltration into the 
alveolar spaces of mouse pups developing lungs, which was reduced when GYY4137 was 
concomitantly administered. The H2S donor limited the macrophage, neutrophil, eosinophil 
and monocyte infiltration into the alveolar air spaces. Thus, the capability of GYY4137 to 
partially restore normal lung alveolarization may be partially explained through the ability of 
GYY4137 to blunt the inflammation caused by 85% O2 in immature developing lungs. 
 Inflammatory cell dynamics was considered to be one mechanism of action through 
which GYY4137 could modulate pro- and anti-inflammatory chemokines and cytokines levels 
in the alveolar airspaces. From the data obtained in this study, hyperoxia exposure increased 
IL-6 levels and decreased IL-10 levels favoring a pro-inflammatory environment in the 
immature mouse lungs. These data is consistent with previous work of other groups, where is 
described that hyperoxia can drive IL-6 production from fetal rat ATII cells (Gavino et al., 
2002), and that IL-6 levels are elevated in a baboon model of BPD (Coalson, 2006). Further 
studies also demonstrated that premature infants express higher IL-6 levels in the BAL which 
is associated with the development of BPD (Bagchi et al., 1994). Concordant with this data, 
there are reports describing that IL-10 levels are dramatically reduced in infants with BPD 
(Jones et al., 1996).  
 Although GYY4137 did not restore the increased IL-6 levels, GYY4137 did normalize 
the IL-10 levels to the developing lung exposed to hyperoxia. Hence, the limited inflammation 
observed in the GYY4137 treated mouse pups exposed to hyperoxia may have been underlie 
by the anti-inflammatory IL-10 activity. Remarkably, the production of IL-10 by fetal rat ATII 
cells can be modulated by anti-oxidant treatment with superoxide dismutase (Johnson-
Varghese et al., 2004), and it has been suggested that IL-10 may protect fetal rat ATII cells 
from apoptosis induced by 85% O2 (Johnson-Varghese et al., 2004; Lee & Kim, 2011). 
Interestingly, infants that are homozygous for the IL-10 “high producer” 1082G allele – a SNP 
 93 
that leads to abnormal higher production of IL10 – are thought to have a lower risk for 
prematurity associated disorders, including BPD (Dordelmann et al., 2006).  
One explanation of how IL-10 may play a protective role in BPD includes the idea that IL-10 
protects fetal ATII cells from the harmful effects of stretch (Lee et al., 2008), and that IL-10 
restricts stretch-induced cytokine secretion by fetal mouse lung fibroblasts (Hawwa et al., 
2011). A side observation from the study was that in 21% O2 GYY4137 treated mouse, 
GYY4137 decreased IL-10 levels, maybe hinting that H2S administration to healthy lungs 
could disturb inflammatory cell lung dynamics. Altogether these data funds the idea that 
GYY4137 protects the lung from the injuring impact of hyperoxia, and that H2S delivered by 
GYY4137 may limit lung inflammation by driving increased IL-10 levels (Madurga et al., 
2014).  
 Apart from the regulation of inflammatory cell dynamics, attention was driven to the 
modulation of gene expression in the lung. Plus, the impact of H2S on epithelial cell migration 
was also considered, since H2S is known to induce endothelial cell migration (Papapetropoulos 
et al., 2009). In the in vitro studies, the fast-release H2S donor NaHS replaced the slow-release 
H2S donor GYY4137, due to the shorter time-course of the in vitro experiments. Prior to 
following studies it was tested that NaHS provoked no cell toxicity at the dose employed. Using 
primary ATII cell pools, a microarray analysis was performed, which demonstrated that ATII 
cells exposed to 85% O2 in vitro for 24 h had a strong impact on gene regulation. Using a very 
stringent criteria, the expression of 251 genes was up-regulated and the expression of 367 genes 
was down-regulated in primary ATII cells in response to normobaric hyperoxia conditions. 
Implementing a PANTHER analysis and taking into account that hyperoxia exposure induces 
apoptosis of lung cells, the microarray analysis resulted in an increase of the p53 pro-apoptosis 
pathway activity, and a decreased in activity of the DNA replication pathway. Though, primary 
ATII cells treated either with H2S donors had no impact on gene modulation, comparing 21% 
O2-treated cells with and without H2S administration, or comparing 85% O2-treated cells with 
and without H2S administration. These data provides conclusive information that H2S delivered 
by NaHS or GYY4137, does not have any direct effect on primary ATII cell gene expression 
per se, and provides information about what H2S is not doing in this system. 
 Though with no modulation on gene expression, exposure of primary ATII cells to 
NaHS did induce ATII cell migration. Certainly, NaHS administration promoted the migration 
capacity of primary ATII cells and fastened wound closure in an in vivo cell monolayer 
wounding assay. These data provides supplementary information for a role of H2S promoting 
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lung repair and restoring normal alveolarization to oxygen-injured lungs (Madurga et al., 
2014).  
Considering that H2S does not influence gene expression in ATII cells, alternative 
candidate pathways that might drive this effect were studied.  
Migration and wound repair of human airway epithelial cells (Trinh et al., 2007) is 
known to be reliant on upon ATP sensitive potassium (KATP) channels. Taking into account 
that the activity of KATP channels may be modulated by H2S (Wang, 2011), glibenclamide, a 
KATP channels inhibitor, was employed in the ATII cell wound repair assay. Glibenclamide 
blunted the ability of NaHS to promote wound closure in ATII cell monolayers. These findings 
support the idea that H2S, delivered by NaHS, promotes ATII cell wound repair through 
modulation of KATP channel activity (Madurga et al., 2014). These data is consistent with 
previous studies where it has been observed that H2S activates KATP channels (Jiang et al., 
2010; Siebert et al., 2008). Still, it is important to consider that glibenclamide is a sulfonylurea 
able to inhibit the cystic fibrosis transmembrane conductance regulator (CFTR) chloride 
channel (Sheppard & Welsh, 1992), and the plausible interactions between H2S with CFTR as 
ATII cell wound repair mediator has not been attempted in this study. 
Protein kinase B (Akt), is another anti-oxidant protective protein in the lung (Lu et al., 
2001), and H2S is known to promote angiogenesis through the Akt pathway (Cai et al., 2007). 
Considering the above mention, primary mouse ATII cells or MLE-12 mouse lung epithelial 
cells exposed to NaHS, resulted in a fast (less than 30 min) activation of Akt, evaluated through 
Akt phosphorylation. These experiments might hint a second mechanism, pointing how H2S 
may protect the lung against hyperoxia-induced injury, promoting wound repair and epithelial 
cell migration. This idea is reinforced by the finding of augmented abundance of activated 
fraction of Akt (phosphorylated) in lung extracts from mouse pup lungs exposed to hyperoxia 
and treated with GYY4137, versus lung extract from mouse pups exposed to hyperoxia and 
treated with vehicle (water) alone. Therefore, GYY4137 administration might have activated 
Akt in vivo in mouse pup lungs exposed to hyperoxia, which could have collaborated to the 
improved lung alveolarization observed in GYY4137-treated mouse pups (Madurga et al., 
2014).  
In this study, it has been demonstrated that H2S administration can partially correct 
defective alveolarization. However, the H2S administration was systemic and not local, which 
is a clear caveat of the study. Still, the systemic administration has a series of advantages; (i) 
enables to properly dose the H2S donor in a pilot study; (ii) avoids possible irritated effects of 
H2S on nursing mothers and the eyes of the newborn pups; and (iii) avoids the quenching of 
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H2S by the very high (85% O2) oxygen levels in the exposure chamber, considering that H2S 
and O2 are highly reactive with one another.  
The data presented in this study deal only with the pulmonary system, although 
systemic administration of H2S delivered by GYY4137 would also affect other organs apart 
from the lung. For example, systemic administration of GYY4137 improved liver and kidney 
failure in an experimental endotoxic shock in rats (determined by attenuated alanine 
aminotransferase and creatinine levels, respectively) (Li et al., 2009), while systemic NaHS 
administration improved renal fibrosis in a rat obstructive nephropathy model (Song et al., 
2014).  
Finally, considering the possible effects of H2S systemic administration on perinatal 
development, rat pups treated systemically with H2S did not suffer growth retardation or 
behavior abnormalities, without any findings of gross developmental abnormalities of the 
brain, heart, liver or kidney (Dorman et al., 2000). 
 
The second central question of this study was: Do cystathionine β-synthase (Cbs) and 
cystathionine γ-lyase (Cth) -both hydrogen sulfide generating and regulatory enzymes- play a 
role during normal late lung development? A starting point for this study was to measure the 
expression levels of both enzymes during different time points during late lung development, 
where the data revealed that both enzymes have a modulated expression in different time points 
during late lung development almost in an opposite manner.  
Secondly, it was measured via laser-capture micro dissection and immunofluorescence 
stainings, where both enzymes are localized in postnatal lungs during two different time points, 
on day P7.5 and on day P14.5. These two time points were chosen because P7.5 is an early 
time point during lung development close to the peak of septation, whereas P14.5 is a later 
stage closer to the micro vessel maturation of the lung (Choi, 2010; Massaro & Massaro, 2007; 
Warburton et al., 2010; Warburton et al., 2000). The data indicated that the both enzymes in 
the mouse, Cbs and Cth, are majoritarely expressed in the vessel and airway compartment with 
a lower expression in the lung parenchyma. This data is consistent to what it has been 
previously described in the literature in adult lungs (Olson et al., 2010; Wang et al., 2011).  
Next, two transgenic mice, where the genes encoding Cbs and Cth have been deleted 
respectively, were tested to study the course of normal late lung development during two time 
points on P7.5 and P14.5. The data from this study describes a dramatic impairment in lung 
development for both Cbs-/- and Cth-/- mice that was fully evident on P14.5. The lung volumes 
of both Cbs-/- and Cth-/- mice were significantly smaller than wild type mice, the values 
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decreased from 0.31 ± 0.01 cm3 in the wild type mice, to 0.23 ± 0.009 cm3 in the Cbs-/- mice 
and to 0.24 ± 0.02 cm3 in the Cth-/- mice. The number of alveoli were significantly smaller in 
both Cbs-/- and Cth-/- mice, it lowered almost 50% when compared to the wild type mice. The 
number of alveoli decreased from 4.74 ± 0.42 × 106 alveoli/both lungs in the wild type mice, 
to 2.30 ± 0.20× 106 alveoli/both lungs in the Cbs-/- mice, and to 2.81 ± 0.78 × 106 alveoli/both 
lungs in the Cth-/- mice. Regarding the mean linear intercept, it changed increasing from 30.85 
± 1.0 µm in wild type mice to 38.15 ± 3.4 µm in the Cbs-/- mice, and it also increased to 43.2 
± 6.8 µm in the Cth-/- mice. Moreover, the surface area for gas exchange was smaller in both 
Cbs-/- and Cth-/- mice when compared to the wild type mice. The values decreased almost 50 
%, ranging from 220.8 ± 13.1 cm2 in the wild type mice, to 134.2 ± 5.9 cm2 in the Cbs-/- mice 
and to 154 ± 22.6 cm2 in the Cth-/- mice. These data confirm that the ablation of both genes Cbs 
and Cth, two generating H2S enzymes, have an impact in the correct developing of the lung 
structure during late lung development. 
Blood vessels in the lung play an important role promoting normal lung development 
and preserving correct alveolar structures throughout alveologenesis. An incorrect or poor 
blood flow distribution may outcome in lung abnormality (Iosef et al., 2012; Pereda et al., 
2013; Thebaud, 2007). Hydrogen sulfide is known to play a role in angiogenesis promoting 
cell growth, motility and capillary morphogenesis, promoting the formation of new vessels 
both in vitro and in vivo (Cai et al., 2007; Papapetropoulos et al., 2009; Perry et al., 2011; 
Szabó, 2011; Vadivel et al., 2014). Prior studies suggest the presence of a vascular network 
former to the morphological construction of the lung (Peng & Morrisey, 2013), and taking into 
an account that both enzymes are present in the vessels, the absence of Cbs and Cth and its 
byproduct H2S, might lead into an error in the pulmonary vasculature, impacting the correct 
growth and maturation of the lung. Indeed, the vascular supply was lower for both Cbs-/- and 
Cth-/- mice postnatal, especially for the Cbs-/- mice, when compared to wild type mice. 
Furthermore, lung homogenates from postnatal Cbs-/- mice and Cth-/- had a lower expression 
of CD31 when compared to wild type mice, which is known to be an effective signaling 
molecule that have different roles in vascular biology which include: Angiogenesis, platelet 
function, thrombosis, mechano-sensing of endothelial cell response to fluid shear stress and 
regulation of multiple stages of leukocyte migration through venular walls (Woodfin et al., 
2007).  
The in vitro experiments corroborated the same findings as the in vivo experiments, 
since the inhibition of both CBS and CTH in HPAECs diminished network formation, but the 
addition of H2S, delivered by GYY4137, promoted it. These data is consistent with the 
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publication of the group of Dr. Thebaud (Vadivel et al., 2014), where they studied the 
protective effects of H2S in preventing pulmonary hypertension in the BPD model. They 
demonstrated in vitro that H2S treatment protects HPAECs from oxygen toxicity and also 
promotes network formation in hyperoxia conditions. They also indicated that H2S lessens 
echographic and structural changes of pulmonary hypertension in vivo. They described that in 
hyperoxia conditions, there is less expression of CD31 in lung homogenates and that the 
expression levels are comparable to room air exposure when treated with H2S. They exposed 
that hyperoxia leads to an arrest of vascular growth by decreasing the number of positive vWF 
lung vessels, and H2S treatment attenuated the loss of vWF positive cells. The study presented 
here also demonstrated that not only the vessel supply is affected in the absence of these two 
enzymes, but also vessel remodeling occurred during lung development in both Cbs-/- mice and 
Cth-/- mice. A thickening of small and medium vessels was present in the Cbs-/- mice, and less 
severe but also present was the remodeling of the small vessels in the Cth-/- mice, which 
correlates with a worse lung development in the case of the Cbs-/- mice compared to the Cth-/- 
mice.  
The absence of both Cbs and Cth not only inhibit the formation of H2S, but also 
promotes the accumulation of homocysteine. Evidence from independent laboratories 
established that hyperhomocysteinemia is associated with vascular dysfunction and 
remodeling. One plausible documented mechanism is oxidative stress: NADPH oxidase causes 
endothelial dysfunction, SMC proliferation and accumulation of extracellular matrix that lead 
to vessel remodeling (Basu et al., 2011). It has been reported that patients with Cbs-/- develop 
severe hyperhomocysteinemia and experience major clinical manifestations of premature 
vascular death if not treated, whereas Cbs+/- individuals live normally but with cardiovascular 
defects (Basu et al., 2011). The accumulation of hyperhomocysteine is considered an 
independent atherogenic risk factor but it has also been shown that administration of NaHS 
protects rat aortic SMCs from the cytotoxicity caused by this molecule (Mani et al., 2013). 
Some groups have described similar findings when studying the role of Cth and H2S in the 
cardiovascular system, in vitro studies indicate that H2S inhibits SMC proliferation and Cth 
deficiency increases it (Mani et al., 2013). Decreased endogenous H2S production predisposes 
animals to vascular remodeling and early development of atherosclerosis. Some molecular 
candidates have been proposed as targets from H2S as inhibitors of vascular SMC proliferation. 
One known pathway is through the mitogen-activated protein kinase (MAPK) (Li et al., 2013); 
other results indicate that H2S via an epigenetic mechanism can involve the inhibition of 
Brahma-related gene 1 (Brg1) transcription and expression, by reducing the recruitment of 
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Brg1 to the proliferating cell nuclear antigen, neurotrophin 3 and platelet-derived growth factor 
subunit A promoting regions (Li et al., 2013). Moreover, other groups have found that the 
treatment with H2S can mitigate the vascular remodeling by normalizing the levels of redox 
stress, matrix metalloproteinase and tissue inhibitor of metalloproteinase (Vacek et al., 2010). 
Although several explanations have been exposed, it is beyond the scope of this study to 
elucidate if the vascular remodeling observed in these Cbs-/- mice and Cth-/- mice is solely due 
to the accumulation of homocysteine or the absence of H2S. Further studies are granted to 
reveal the complex mechanisms that are responsible for the vessel alteration observed in the 
Cbs-/- and Cth-/- mice.  
The data presented in this study indicate that H2S administration can diminish the 
harmful effects of hyperoxia on lung alveolarization, and some candidate mechanisms have 
been exposed to explain this phenomenon, including the capacity of H2S to drive production 
of protective anti-inflammatory cytokines, limit the inflammatory cell recruitment to the 
alveolar airspaces (mostly macrophages and neutrophils) that was provoked by hyperoxia, and 
to promote ATII wound healing and cell migration through glibenclamide-sensitive ion 
channels, and possibly through the activation of the lung-protective Akt pathway.  
The data also indicates the possible role of the two generating H2S enzymes Cbs and 
Cth, during the course of normal late lung development, the expression and localization of 
these enzymes in postnatal lung mice have been presented, together with the lung structural 
analysis of the Cbs-/- mice and Cth-/- mice showing an aberrant alveolarization and vessel 
maturation in vitro and in vivo. 
The data presented in this study, provides solid support to continue evaluating H2S as a 
novel agent that might prove useful in the management of hyperoxia-induced injury to the 
developing lung. This possibility is far more attractive, considering the potential delivery of 
H2S locally via the trachea to the developing lungs, which would be a feasible process in 
intubated, ventilated patients.  
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